Subcutaneous dosing of Anti-LAG-3 and Anti-PD-1 antibodies and uses thereof
Subcutaneous administration of anti-LAG-3 and anti-PD-1 antibodies with an endoglycosidase hydrolase enzyme in a single unit dose addresses the challenges of intravenous infusion, enhancing dosing accuracy and reducing costs for tumor treatment.
Patent Information
- Application Number
- PCT/US2026/027160
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current methods of administering anti-PD-1 and anti-LAG-3 antibodies for tumor treatment involve intravenous infusion, which can lead to dosing errors, require extensive preparation time, and are costly, making self-administration difficult.
Subcutaneous administration of anti-LAG-3 and anti-PD-1 antibodies, along with an endoglycosidase hydrolase enzyme, in a single unit dose, providing improved dosing accuracy and ease of use, allowing for potential self-administration at home.
The subcutaneous method reduces the risk of dosing errors, decreases administration time, and lowers healthcare costs while enabling easier and more accurate treatment administration.
Smart Images

Figure IMGF000096_0001_TABLE 
Figure IMGF000123_0001_TABLE 
Figure IMGF000124_0001_TABLE
Abstract
Description
SUBCUTANEOUS DOSING OF ANTI-LAG-3 AND ANTI-PD-1 ANTIBODIES AND USES THEREOF CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This PCT application claims the priority benefit of U. S. Provisional Application No. 63 / 801,646, filed May 7, 2025, which is incorporated herein by reference in its entirety.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0002] The content of the electronically submitted sequence listing (Name: 3338_345PC01_SequenceListing_ST26; Size: 491, 174 Bytes; and Date of Creation: May 5, 2026), filed with the application, is herein incorporated by reference in its entirety.FIELD OF THE INVENTION
[0003] The present disclosure provides methods of treating a tumor in a subject by subcutaneous administration of anti -LAG-3 and anti-PD-1 antibodies.BACKGROUND OF THE INVENTION
[0004] Anti-PD-1 and anti -LAG-3 antibodies are currently administered in an intravenous (IV) infusion to patients. Subcutaneous administration would provide several benefits, including: a decreased risk of potential dosing errors that can occur during preparation of infusions, improved dosing accuracy when compared to the preparation of infusions, ease of use, a decrease in the time required for administration, a decrease in healthcare costs, and the potential for self-administration at home.
[0005] There is a need for methods of treating tumors in subjects by subcutaneous administration of anti -LAG-3 and anti-PD-1 antibodies.SUMMARY OF THE DISCLOSURE
[0006] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg or about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mgto about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose. In some aspects the anti-PD-1 antibody is administered to the subject at a dose of about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 800 mg, about 880 mg, about 960 mg, about 1020 mg, about 1080 mg, about 1140 mg, or about 1200 mg.
[0007] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0008] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0009] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 800 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0010] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0011] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) anendoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0012] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0013] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0014] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0015] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0016] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 800 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0017] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0018] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0019] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0020] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0021] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0022] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) anendoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0023] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 800 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0024] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0025] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0026] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0027] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0028] In some aspects, the single unit dose has a volume of about 9 mL to about 16 mL.
[0029] In some aspects, the single unit dose is administered once about every two, three, or four weeks.
[0030] In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 18,000 IU, about 19,000 IU, about 20,000 IU, about 21,000 IU, about 22,000 IU, about 23,000 IU, about 24,000 IU, about 25,000 IU, about 26,000 IU, about 27,000 IU, about 28,000 IU, about 29,000 IU, about 30,000 IU, about 31,000 IU, or about 32,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 32,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 30,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 26,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 24,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 22,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 20,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 19,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 18,000 IU.
[0031] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 16 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 120 mg / mL.
[0032] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 16,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 8 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 120 mg / mL.
[0033] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 12 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 120 mg / mL.
[0034] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 30,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 15 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 128 mg / mL.
[0035] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 15,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 7.5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 128 mg / mL.
[0036] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 22,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 11.25 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 128 mg / mL.
[0037] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 25,600 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 12.8 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0038] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of 12,800 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 6.4 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0039] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 19,200 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 9.6 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0040] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 12 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 160 mg / mL.
[0041] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of 12,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 6 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 160 mg / mL.
[0042] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 9 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 160 mg / mL.
[0043] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 16 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0044] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 16,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 8 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0045] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 12 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0046] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 9 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 160 mg / mL.
[0047] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 9,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 4.5 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 160 mg / mL.
[0048] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 13,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 6.75 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 160 mg / mL.
[0049] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 19,200 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 9.6 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0050] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 9,600 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 4.8 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0051] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 14,400 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 7.2 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0052] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 20,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 10 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 144 mg / mL.
[0053] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 10,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 144 mg / mL.
[0054] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 15,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 7.5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 144 mg / mL.
[0055] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 12 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0056] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 12,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 6 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0057] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 9 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0058] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 16,800 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 8.4 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0059] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 8,400 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 4.2 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0060] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 12,600 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 6.3 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0061] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 9 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 140 mg / mL.
[0062] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 9,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 4.5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 140 mg / mL.
[0063] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 13,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 6.75 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 140 mg / mL.
[0064] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 20,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 10 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 126 mg / mL.
[0065] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 10,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 126 mg / mL.
[0066] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 15,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 7.5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 126 mg / mL.
[0067] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme hyaluronidase at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 12 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 105 mg / mL.
[0068] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme hyaluronidase at a dose of about 12,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 6 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 105 mg / mL.
[0069] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme hyaluronidase at a dose of about 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 9 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 105 mg / mL.
[0070] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 480 mg to about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg to about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose. In some aspects, the single unit dose is administered to the subject once about every two, three, or four weeks. In some aspects, the anti -LAG-3 antibody is administered at a dose of about 540 mg to about 1200 mg, about 600 mg to about 1200 mg, about 660 mg to about 1200 mg, about 720 mg to about 1200 mg, about 780 mg to about 1200 mg, about 840 mg to about 1200 mg, about 900 mg to about 1200 mg, about 960 mg to about 1200 mg, about 1020 mg to about 1200 mg, about 1080 mg to about 1200 mg, about 1140 mg to about 1200 mg, about 480 mg to about 1140 mg, about 540 mg to about 1140 mg, about 600 mg to about 1140 mg, about 660 mg to about 1140 mg, about 720 mg to about 1140 mg, about 780 mg to about 1140 mg, about 840 mg to about 1140 mg, about 900 mg to about 1140 mg, about 960 mg to about 1140 mg, about 1020 mg to about 1140 mg, about 1080 mg to about 1140 mg, about 480 mg to about 1080 mg, about 540 mg to about 1080 mg, about 600 mg to about 1080 mg, about 660 mg to about 1080 mg, about 720 mg to about 1080 mg, about 780 mg to about 1080 mg, about 840 mg to about 1080 mg, about 900 mg to about 1080 mg, about 960 mg to about 1080 mg, about 1020 mg to about 1080 mg, about 480 mg to about 1020 mg, about 540 mg to about 1020 mg, about 600 mg to about 1020 mg, about 660 mg to about 1020 mg, about 720 mg to about 1020 mg, about 780 mg to about 1020 mg, about 840 mg to about 1020 mg, about 900 mg to about 1020 mg, about 960 mg to about 1020 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 900 mg to about 960 mg, about 480 mg to about 900 mg, about 540 mg to about 900 mg, about 600 mg to about 900 mg, about 660 mg to about900 mg, about 720 mg to about 900 mg, about 780 mg to about 900 mg, about 840 mg to about 900 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, or about 480 mg to about 540 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, about 960 mg, about 1020 mg, about 1080 mg, about 1140 mg, or about 1200 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 540 mg to about 1200 mg, about 600 mg to about 1200 mg, about 660 mg to about 1200 mg, about 720 mg to about 1200 mg, about 780 mg to about 1200 mg, about 840 mg to about 1200 mg, about 900 mg to about 1200 mg, about 960 mg to about 1200 mg, about 1020 mg to about 1200 mg, about 1080 mg to about 1200 mg, about 1140 mg to about 1200 mg, about 480 mg to about 1140 mg, about 540 mg to about 1140 mg, about 600 mg to about 1140 mg, about 660 mg to about 1140 mg, about 720 mg to about 1140 mg, about 780 mg to about 1140 mg, about 840 mg to about 1140 mg, about 900 mg to about 1140 mg, about 960 mg to about 1140 mg, about 1020 mg to about 1140 mg, about 1080 mg to about 1140 mg, about 480 mg to about 1080 mg, about 540 mg to about 1080 mg, about 600 mg to about 1080 mg, about 660 mg to about 1080 mg, about 720 mg to about 1080 mg, about 780 mg to about 1080 mg, about 840 mg to about 1080 mg, about 900 mg to about 1080 mg, about 960 mg to about 1080 mg, about 1020 mg to about 1080 mg, about 480 mg to about 1020 mg, about 540 mg to about 1020 mg, about 600 mg to about 1020 mg, about 660 mg to about 1020 mg, about 720 mg to about 1020 mg, about 780 mg to about 1020 mg, about 840 mg to about 1020 mg, about 900 mg to about 1020 mg, about 960 mg to about 1020 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 900 mg to about 960 mg, about 480 mg to about 900 mg, about 540 mg to about 900 mg, about 600 mg to about 900 mg, about 660 mg to about 900 mg, about 720 mg to about 900 mg, about 780 mg to about 900 mg, about 840 mg to about 900 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg,about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, or about 480 mg to about 540 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, about 960 mg, about 1020 mg, about 1080 mg, about 1140 mg, or about 1200 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 480 mg and the anti-PD-1 antibody is administered at a dose of about 480 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 540 mg and the anti-PD-1 antibody is administered at a dose of about 540 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 600 mg and the anti-PD-1 antibody is administered at a dose of about 600 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 660 mg and the anti-PD-1 antibody is administered at a dose of about 660 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 720 mg and the anti-PD-1 antibody is administered at a dose of about 720 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 780 mg and the anti-PD-1 antibody is administered at a dose of about 780 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 840 mg and the anti-PD-1 antibody is administered at a dose of about 840 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 900 mg and the anti-PD-1 antibody is administered at a dose of about 900 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 960 mg and the anti-PD-1 antibody is administered at a dose of about 960 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 1020 mg and the anti-PD-1 antibody is administered at a dose of about 1020 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 1080 mg and the anti-PD-1 antibody is administered at a dose of about 1080 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 1140 mg and the anti-PD-1 antibody is administered at a dose of about 1140 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 1200 mg and the anti-PD-1 antibody is administered at a dose of about 1200 mg.
[0071] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 240 mg to about 600 mg, (ii) an anti-PD-1 antibody at a dose of about 240 mg to about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolaseenzyme are formulated in a single unit dose. In some aspects, the single unit dose is administered to the subject once about every two weeks. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 300 mg to about 600 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 240 mg to about 540 mg, about 300 mg to about 540 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 240 mg to about 480 mg, about 300 mg to about 480 mg, about 360 mg to about 480 mg, about 420 mg to about 480 mg, about 240 mg to about 420 mg, about 300 mg to about 420 mg, about 360 mg to about 420 mg, about 240 mg to about 360 mg, about 300 mg to about 360 mg, or about 240 mg to about 300 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 240 mg, about 300 mg, about 360 mg, about 420 mg, about 480 mg, about 540 mg, or about 600 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 300 mg to about 600 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 240 mg to about 540 mg, about 300 mg to about 540 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 240 mg to about 480 mg, about 300 mg to about 480 mg, about 360 mg to about 480 mg, about 420 mg to about 480 mg, about 240 mg to about 420 mg, about 300 mg to about 420 mg, about 360 mg to about 420 mg, about 240 mg to about 360 mg, about 300 mg to about 360 mg, or about 240 mg to about 300 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 240 mg, about 300 mg, about 360 mg, about 420 mg, about 480 mg, about 540 mg, or about 600 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 480 mg and the anti-PD-1 antibody is administered at a dose of about 480 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 540 mg and the anti-PD-1 antibody is administered at a dose of about 540 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 600 mg and the anti-PD-1 antibody is administered at a dose of about 600 mg.
[0072] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg to about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg to about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose. In some aspects, the single unit dose is administered to the subject once about every three or four weeks. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 420 mg to about 960 mg, about 480 mg to about 960 mg, about540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 360 mg to about 840 mg, about 420 mg to about 840 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 360 mg to about 780 mg, about 420 mg to about 780 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 360 mg to about 720 mg, about 420 mg to about 720 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 360 mg to about 660 mg, about 420 mg to about 660 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 360 mg to about 480 mg, about 420 mg to about 480 mg, or about 360 mg to about 420 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 360 mg, about 420 mg, about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, or about 960 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 420 mg to about 960 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 360 mg to about 840 mg, about 420 mg to about 840 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 360 mg to about 780 mg, about 420 mg to about 780 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 360 mg to about 720 mg, about 420 mg to about 720 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 360 mg to about 660 mg, about 420 mg to about 660 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 360 mg to about 480 mg, about 420 mg to about 480 mg, or about 360 mg to about 420 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 360 mg, about 420 mg, about 480 mg, about540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, or about 960 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 420 mg and the anti-PD-1 antibody is administered at a dose of about 420 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 480 mg and the anti-PD-1 antibody is administered at a dose of about 480 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 540 mg and the anti-PD-1 antibody is administered at a dose of about 540 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 600 mg and the anti-PD-1 antibody is administered at a dose of about 600 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 660 mg and the anti-PD-1 antibody is administered at a dose of about 660 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 720 mg and the anti-PD-1 antibody is administered at a dose of about 720 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 780 mg and the anti-PD-1 antibody is administered at a dose of about 780 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 840 mg and the anti-PD-1 antibody is administered at a dose of about 840 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 900 mg and the anti-PD-1 antibody is administered at a dose of about 900 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 960 mg and the anti-PD-1 antibody is administered at a dose of about 960 mg.
[0073] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
[0074] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 600 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
[0075] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) anendoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
[0076] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
[0077] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 900 mg, (ii) an anti-PD-1 antibody at a dose of about 900 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
[0078] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
[0079] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
[0080] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
[0081] In some aspects, the single unit dose comprises a total antibody concentration of about 100 mg / mL or more. In some aspects, the single unit dose comprises a total antibody concentration of about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about 110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL to about 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115 mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120 mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL. In some aspects, the single unit dose comprises a total antibody concentration of about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about 125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL. In some aspects, the single unit dose comprises a total antibody concentration of about 105 mg / mL, about 120 mg / mL, about 126 mg / mL, about 128 mg / mL, about 140 mg / mL, about 144 mg / mL, about 150 mg / mL, or about 160 mg / mL.
[0082] In some aspects, the single unit dose comprises a volume of about 0.001 mL to about 20 mL. In some aspects, the single unit dose comprises a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL, about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL, about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL,about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about 5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL, about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, about 11.5 mL, about 11.6 mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about 13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL, about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2 mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL. In some aspects, the single unit dose comprises a volume of about 8.4 mL, about 9 mL, about 9.6 mL, about 10 mL, about 12 mL, about 12.8 mL, about 15 mL, or about 16 mL.
[0083] In some aspects, the anti-LAG-3 antibody comprises a full-length antibody.
[0084] In some aspects, the anti-PD-1 antibody comprises a full-length antibody.
[0085] In some aspects, the anti-LAG-3 antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody. In some aspects, the multispecific antibody comprises a dual-affinity re-targeting antibody, a dual variable domain immunoglobulin, or a bispecific antibody.
[0086] In some aspects, the anti-PD-1 antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody. In some aspects, the multispecific antibody comprises a dual-affinity re-targeting antibody, a dual variable domain immunoglobulin, or a bispecific antibody.
[0087] In some aspects, the anti -LAG-3 antibody and / or the anti-PD-1 antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.
[0088] In some aspects, the anti -LAG-3 antibody comprises BMS-986016 (relatlimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, ieramilimab), aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBL110, EMB-02, IBL 323, LBL-007, ABL501, or an antigen binding portion thereof.
[0089] In some aspects, the anti-LAG-3 antibody comprises relatlimab, or an antigen binding portion thereof.
[0090] In some aspects, the anti-LAG-3 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively; (d) heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:l and 2, respectively; or (e) heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:21 and 2, respectively.
[0091] In some aspects, the anti-PD-1 antibody comprises nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDI-0680, TSR-042, cemiplimab, JS001, PF-06801591, BGB-A317, BI 754091, INCSHR1210, GLS-010, AM-001, STI-1110, AGEN2034, MGA012, BCD-100, IB 1308, SSI-361, or an antigen binding portion thereof.
[0092] In some aspects, the anti-PD-1 antibody comprises nivolumab, or an antigen binding portion thereof.
[0093] In some aspects, the anti-PD-1 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs: 13 and 14, respectively; or (d) heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs: 11 and 12, respectively.
[0094] In some aspects, the single unit dose comprises about 80 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose comprises a volume of about 12 mL. In some aspects, the single unit dose comprises a volume of about 9 mL.
[0095] In some aspects, the single unit dose comprises about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose comprises a volume of about 12.8 mL. In some aspects, the single unit dose comprises a volume of about 9.6 mL.
[0096] In some aspects, the single unit dose comprises about 72 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose comprises a volume of about 10 mL.
[0097] In some aspects, the single unit dose comprises about 64 mg / mL of the anti-PD-1 antibody and about 64 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose comprises a volume of about 15 mL.
[0098] In some aspects, the single unit dose comprises about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose has a volume of about 16 mL. In some aspects, the single unit dose has a volume of about 12 mL.
[0099] In some aspects, the single unit dose comprises about 64.3 mg / mL of the anti-PD-1 antibody and about 85.7 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose has a volume of about 8.4 mL.
[0100] In some aspects, the single unit dose comprises about 60 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose has a volume of about 9 mL.
[0101] In some aspects, the single unit dose comprises about 54 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose has a volume of about 10 mL.
[0102] In some aspects, the single unit dose comprises about 45 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose has a volume of about 12 mL.
[0103] In some aspects, the anti-LAG-3 antibody comprises relatlimab, or an antigen binding portion thereof, and the anti-PD-1 antibody comprises nivolumab, or an antigen binding portion thereof.
[0104] In some aspects, the endoglycosidase hydrolase enzyme cleaves hyaluronic acid at a hexosaminidic P (1-4) or (1-3) linkage.
[0105] In some aspects, the endoglycosidase hydrolase enzyme comprises a catalytic domain of hyaluronidase PH-20 (HuPH20), HYAL1, HYAL2, HYAL3, HYAL4, or HYALPS1.
[0106] In some aspects, the endoglycosidase hydrolase enzyme comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to amino acids 36-490 of SEQ ID NO:87.
[0107] In some aspects, the endoglycosidase hydrolase enzyme comprises a hyaluronidase. In some aspects, the hyaluronidase comprises HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, or a variant or isoform thereof.
[0108] In some aspects, the endoglycosidase hydrolase enzyme comprises rHuPH20 or a fragment thereof.
[0109] In some aspects, the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising one or more amino acid substitutions relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof.
[0110] In some aspects, the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising (i) one or more amino acid substitution in an alpha-helix region, (ii) one or more amino acid substitution in a linker region, (iii) deletion of one or more N-terminal and / or C-terminal amino acids, or (iv) any combination of (i)-(iii), relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof.
[0111] In some aspects, the endoglycosidase hydrolase enzyme comprises a modified rHuPH20, wherein the modified rHuPH20 comprises: (a) one or more amino acid substitution inan alpha-helix region, a linker region, or both an alpha-helix region and a linker region relative to wild-type rHuPH20; (b) deletion of one or more N-terminal amino acid, one or more C-terminal amino acid, or one or more N-terminal amino acid and one or more C-terminal amino acid relative to wild-type rHuPH20; or (c) both (a) and (b).
[0112] In some aspects, the tumor comprises a hepatocellular carcinoma, colorectal cancer, gastric cancer, small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), squamous NSCLC, nonsquamous NSCLC, solid cancer with liver metastatic disease, cervical cancer, breast cancer, triple-negative breast cancer, pancreatic cancer, urothelial cancer, prostate cancer, hormone refractory prostate adenocarcinoma, hematological cancer, squamous cell carcinoma, glioma, gastrointestinal cancer, renal cancer, clear cell carcinoma, ovarian cancer, liver cancer, endometrial cancer, kidney cancer, renal cell carcinoma (RCC), thyroid cancer, neuroblastoma, glioblastoma, glioblastoma multiforme, stomach cancer, bladder cancer, hepatoma, colon cancer, head and neck cancer, gastroesophageal cancer, germ cell tumor, pediatric sarcoma, sinonasal natural killer T-cell lymphoma, melanoma, bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, rectal cancer, solid tumor of childhood, cancer of the ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumor, brain cancer, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, environmentally-induced cancer, virus-related cancer or cancer of viral origin, or a combination thereof.
[0113] In some aspects, the tumor is recurrent or refractory.
[0114] In some aspects, the tumor is unresectable, advanced, and / or metastatic.
[0115] In some aspects, the tumor is a malignant tumor.
[0116] In some aspects, the dose of the anti-LAG-3 antibody, anti-PD-1 antibody, and / or endoglycosidase hydrolase enzyme is a flat dose.
[0117] In some aspects, the minimum serum concentration at day 28 (CminD28), the average serum concentration at day 28 (CavgD28), the minimum serum concentration at steady state (CminSS), and / or the average serum concentration at steady state (CavgSS) of the anti-PD-1 antibody in the subject (e.g., a subject to whom 720 mg or more of the anti-PD-1 antibody has been administered once about every three or four weeks) is about equal to or greater than the geometricmean CminD28, CavgD28, CminSS, and / or CavgSS, respectively, of nivolumab in a population of subjects in which 480 mg of nivolumab is intravenously administered once about every four weeks to each subject in the population.
[0118] In some aspects, the CminD28, CavgD28, CminSS, and / or CavgSS of the anti-L AG-3 antibody in the subj ect (e.g., a subj ect to whom 720 mg or more of the anti -LAG-3 antibody has been administered once about every three or four weeks) is about equal to or greater than the geometric mean CminD28, CavgD28, CminSS, and / or CavgSS, respectively, of relatlimab in a population of subjects in which 480 mg of relatlimab is intravenously administered once about every four weeks to each subject in the population.
[0119] In some aspects, the CminD28, CavgD28, CminSS, and / or CavgSS of the anti-L AG-3 antibody in the subj ect (e.g., a subj ect to whom 540 mg or more of the anti -LAG-3 antibody has been administered once about every three weeks) is about equal to or greater than the geometric mean CminD28, CavgD28, CminSS, and / or CavgSS, respectively, of relatlimab in a population of subjects in which 360 mg of relatlimab is intravenously administered once about every three weeks to each subject in the population.
[0120] In some aspects, the method further comprises administering an additional anticancertherapy. In some aspects, the additional anti-cancer therapy comprises a surgery, a radiation therapy, a chemotherapy, an immunotherapy, or any combination thereof. In some aspects, the additional anti-cancer therapy comprises a chemotherapy.BRIEF DESCRIPTION OF THE DRAWINGS
[0121] FIG. 1 shows a simulated nivolumab concentration-time profile for doses of 480 mg administered intravenously every 4 weeks (“IV 480 mg Q4W”), 720 mg administered subcutaneously every 4 weeks (“SC 720 mg Q4W”), 800 mg administered subcutaneously every 4 weeks (“SC 800 mg Q4W”), and 960 mg administered subcutaneously every 4 weeks (“SC 960 mg Q4W”) in a 79% bioavailability scenario. Nivo Geo Mean = nivolumab geometric mean.
[0122] FIG. 2 shows observed relatlimab concentration-time curves following a single subcutaneous dose of either 480 mg or 720 mg to subjects in a Phase I clinical study.
[0123] FIG. 3 shows a simulated relatlimab concentration-time profile for a dose of 480 mg administered intravenously every 4 weeks (“480 mg Q4W IV”) as compared to a dose of 960 mg administered subcutaneously every 4 weeks (“960 mg Q4W SC”) in a 58% bioavailability scenario.
[0124] FIGs. 4A-4C show predicted relatlimab exposures in a 58% BA scenario for a dose of 480 mg administered intravenously every 4 weeks (“480 mg Q4W IV”) as compared to 720 mg administered subcutaneously every 4 weeks (“720 mg Q4W SC”), 840 mg administered subcutaneously every 4 weeks (“840 mg Q4W SC”), and 960 mg administered subcutaneously every 4 weeks (“960 mg Q4W SC”). FIG. 4A shows the relatlimab geometric mean average concentrations for the dose groups at day 28 (“CavgD28”). FIG. 4B shows the relatlimab geometric mean minimum concentrations for the dose groups at day 28 (“CminD28”). FIG. 4C shows the relatlimab geometric mean maximum concentrations for the dose groups following the first dose (“Cmaxl”).DETAILED DESCRIPTION OF THE INVENTION
[0125] The present disclosure provides methods of treating a tumor in a subject comprising subcutaneously administering doses of an anti-LAG-3 antibody (e.g., an anti -LAG-3 antibody comprising the CDRs of relatlimab), an anti-PD-1 antibody (e.g, an anti-PD-1 antibody comprising the CDRs of nivolumab), and an endoglycosidase hydrolase enzyme (e.g, rHuPH20) that are formulated in a single unit dose.I. Terms
[0126] In order that the present disclosure can be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application. It is to be noted that the term "a" or "an" entity refers to one or more of that entity; for example, "a protein," is understood to represent one or more proteins. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.
[0127] The term "and / or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and / or" as used in a phrase such as " A and / or B" herein is intended to include " A and B," " A or B," " A" (alone), and " B" (alone). Likewise, the term "and / or" as used in a phrase such as " A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0128] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of' and / or "consisting essentially of' are also provided.
[0129] The terms "about" or "comprising essentially of' refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, z.e., the limitations of the measurement system. For example, "about" or "comprising essentially of can mean within 1 or more than 1 standard deviation per the practice in the art. Alternatively, "about" or "comprising essentially of' can mean a range of up to 10% or 20% (z.e., ±10% or ±20%). In some aspects, "about" comprises a range of up to 10% (z.e., ±10%). In some aspects, "about" comprises a range of up to 20% (z.e., ±20%). For example, about 3 mg can include any number between 2.7 mg and 3.3 mg (for 10%) or between 2.4 mg and 3.6 mg (for 20%). Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of "about" or "comprising essentially of' should be assumed to be within an acceptable error range for that particular value or composition.
[0130] As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.
[0131] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 5th ed., 2013, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, 2006, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.
[0132] Units, prefixes, and symbols are denoted in their Systeme International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range.
[0133] The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.
[0134] An "antibody" (Ab) shall include, without limitation, a glycoprotein immunoglobulin which binds specifically to an antigen and comprises at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each H chain comprises a heavy chainvariable region (abbreviated herein as NH) and a heavy chain constant region (abbreviated herein as CH). The heavy chain constant region comprises three constant domains, CHI, CHI and Cm. Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region (abbreviated herein as CL). The light chain constant region comprises one constant domain, CL. The NH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each NH and VL comprises three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. A heavy chain can have the C-terminal lysine or not. Unless specified otherwise herein, the amino acids in the variable regions are numbered using the Kabat numbering system and those in the constant regions are numbered using the EU system.
[0135] An immunoglobulin can derive from any of the commonly known isotypes, including but not limited to IgA, secretory IgA, IgG and IgM. IgG subclasses are also well known to those in the art and include but are not limited to human IgGl, IgG2, IgG3 and IgG4. " Isotype" refers to the antibody class or subclass (e.g., IgM or IgGl) that is encoded by the heavy chain constant region genes. The term "antibody" includes, by way of example, both naturally occurring and non-naturally occurring antibodies; monoclonal and polyclonal antibodies; chimeric and humanized antibodies; human or nonhuman antibodies; wholly synthetic antibodies; single chain antibodies; monospecific antibodies; bispecific antibodies; and multi-specific antibodies. A nonhuman antibody can be humanized by recombinant methods to reduce its immunogenicity in humans. Where not expressly stated, and unless the context indicates otherwise, the term "antibody" also includes an antigen binding fragment or an antigen binding portion of any of the aforementioned immunoglobulins, and includes a monovalent and a divalent fragment or portion, that retains the ability to bind specifically to the antigen bound by the whole immunoglobulin. Examples of an "antigen binding portion" or "antigen binding fragment" include: (1) a Fab fragment (fragment from papain cleavage) or a similar monovalent fragment consisting of the VL, NH, LC and CHI domains; (2) a F(ab')2 fragment (fragment from pepsin cleavage) or a similar bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (3) a Fd fragment consisting of the VH and CHI domains; (4) a Fv fragment consisting of the VLand NH domains of a single arm of an antibody; (5) a single domain antibody (dAb) fragment (Ward et aL, (1989) Nature 341:544-46), which consists of a NH domain; (6) a bi-single domain antibody which consists of two NH domains linked by a hinge (dual-affinity re-targeting antibodies (DARTs)); or (7) a dual variable domain immunoglobulin. Furthermore, although the two domains of the Fv fragment, NL and NH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the NL and NH regions pair to form monovalent molecules (known as single chain Fv (scFv); see, e.g., Bird etal. (1988) Science 242:423-426; and Huston etal. N )Proc. Natl. Acad. Sci. USA 85:5879-5883).
[0136] An "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that binds specifically to LAG-3 is substantially free of antibodies that do not bind specifically to LAG-3). An isolated antibody that binds specifically to LAG-3 can, however, have cross-reactivity to other antigens, such as LAG-3 molecules from different species. Moreover, an isolated antibody can be substantially free of other cellular material and / or chemicals.
[0137] The term "monoclonal antibody" ("mAb") refers to a non-naturally occurring preparation of antibody molecules of single molecular composition, i.e., antibody molecules whose primary sequences are essentially identical, and which exhibits a single binding specificity and affinity for a particular epitope. A mAb is an example of an isolated antibody. MAbs can be produced by hybridoma, recombinant, transgenic or other techniques known to those skilled in the art.
[0138] A "human" antibody (HuMAb) refers to an antibody having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. The human antibodies of the invention can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody," as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. The terms "human" antibodies and "fully human" antibodies and are used synonymously.
[0139] A "humanized antibody" refers to an antibody in which some, most or all of the amino acids outside the CDR domains of a non-human antibody are replaced with correspondingamino acids derived from human immunoglobulins. In some aspects of a humanized form of an antibody, some, most or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulins, whereas some, most or all amino acids within one or more CDR regions are unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they do not abrogate the ability of the antibody to bind to a particular antigen. A "humanized" antibody retains an antigenic specificity similar to that of the original antibody.
[0140] A "chimeric antibody" refers to an antibody in which the variable regions are derived from one species and the constant regions are derived from another species, such as an antibody in which the variable regions are derived from a mouse antibody and the constant regions are derived from a human antibody.
[0141] An "anti-antigen" antibody refers to an antibody that binds specifically to the antigen. For example, an anti-LAG-3 antibody binds specifically to LAG-3.
[0142] " LAG-3" refers to Lymphocyte Activation Gene-3. The term " LAG-3" includes variants, isoforms, homologs, orthologs and paralogs. For example, antibodies specific for a human LAG-3 protein can, in certain cases, cross-react with a LAG-3 protein from a species other than human. In some aspects, the antibodies specific for a human LAG-3 protein can be completely specific for the human LAG-3 protein and not exhibit species or other types of cross-reactivity, or can cross-react with LAG-3 from certain other species, but not all other species (e.g., cross-react with monkey LAG-3 but not mouse LAG-3). The term "human LAG-3" refers to human sequence LAG-3, such as the complete amino acid sequence of human LAG-3 having GenBank Accession No. NP_002277. The term "mouse LAG-3" refers to mouse sequence LAG-3, such as the complete amino acid sequence of mouse LAG-3 having GenBank Accession No. NP 032505. LAG-3 is also known in the art as, for example, CD223. The human LAG-3 sequence can differ from human LAG-3 of GenBank Accession No. NP_002277 by having, e.g, conserved mutations or mutations in non-conserved regions, and the LAG-3 has substantially the same biological function as the human LAG-3 of GenBank Accession No. NP 002277. For example, a biological function of human LAG-3 is having an epitope in the extracellular domain of LAG-3 that is specifically bound by an antibody of the instant disclosure or a biological function of human LAG-3 is binding to MHC Class II molecules.
[0143] A particular human LAG-3 sequence will generally be at least about 90% identical in amino acid sequence to human LAG-3 of GenBank Accession No. NP 002277 and contains amino acid residues that identify the amino acid sequence as being human when compared to LAG-3 amino acid sequences of other species (e.g., murine). In certain cases, a human LAG-3 can be at least about 95%, or even at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical in amino acid sequence to LAG-3 of GenBank Accession No. NP 002277. In some aspects, a human LAG-3 sequence will display no more than 10 amino acid differences from the LAG-3 sequence of GenBank Accession No. NP_002277. In some aspects, the human LAG-3 can display no more than 5, or even no more than 4, 3, 2, or 1 amino acid difference from the LAG-3 sequence of GenBank Accession No. NP_002277.
[0144] " Programmed Death-1 (PD-1)" refers to an immunoinhibitory receptor belonging to the CD28 family. PD-1 is expressed predominantly on previously activated T cells in vivo, and binds to two ligands, PD-L1 and PD-L2. The term " PD-1" as used herein includes human PD-1 (hPD-1), variants, isoforms, and species homologs of hPD-1, and analogs having at least one common epitope with hPD-1. The complete hPD-1 sequence can be found under GenBank Accession No. U64863. " PD-1" and " PD-1 receptor" are used interchangeably herein.
[0145] " Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4)" refers to an immunoinhibitory receptor belonging to the CD28 family. CTLA-4 is expressed exclusively on T cells in vivo, and binds to two ligands, CD80 and CD86 (also called B7-1 and B7-2, respectively). The term " CTLA-4" as used herein includes human CTLA-4 (hCTLA-4), variants, isoforms, and species homologs of hCTLA-4, and analogs having at least one common epitope with hCTLA-4. The complete hCTLA-4 sequence can be found under GenBank Accession No. AAB59385.
[0146] " Programmed Death Ligand- 1 (PD-L1)" is one of two cell surface glycoprotein ligands for PD- 1 (the other being PD-L2) that downregulate T cell activation and cytokine secretion upon binding to PD-1. The term " PD-L1" as used herein includes human PD-L1 (hPD-Ll), variants, isoforms, and species homologs of hPD-Ll, and analogs having at least one common epitope with hPD-Ll. The complete hPD-Ll sequence can be found under GenBank Accession No. Q9NZQ7.
[0147] " Programmed Death Ligand-2 (PD-L2)" as used herein includes human PD-L2 (hPD-L2), variants, isoforms, and species homologs of hPD-L2, and analogs having at least one common epitope with hPD-L2. The complete hPD-L2 sequence can be found under GenBank Accession No. Q9BQ51.
[0148] " Hyaluronidase," as used herein, refers to an enzyme capable of catalyzing the cleavage of hyaluronan. Hyaluronan is a repeating polymer of N-acetyl-glucosamine and glucuronic acid, which is present in the subcutaneous space and contributes to the soluble gel-like component of the extracellular matrix of the skin and is restored by rapid turnover (resynthesis).In some aspects, the hyaluronidase comprises rHuPH20, which is a glycosylated 447-amino acid single chain polypeptide that depolymerizes hyaluronan in the subcutaneous space locally at the site of injection in the skin. Depolymerization of hyaluronan by hyaluronidase is accomplished by hydrolysis of the polysaccharide polymer. Depolymerization of hyaluronan results in a transient reduction in the viscosity of the gel-like phase of the extracellular matrix and increased hydraulic conductance that facilitates the dispersion and absorption of the coadministered therapeutic agent. Thus, a hyaluronidase, e.g., rHuPH20, can improve the speed and ease of subcutaneous delivery of injectable biologies and drugs by acting as a permeation enhancer. In some aspects, the hyaluronidase comprises ENHANZE.
[0149] A "subject" as used herein includes any human who is afflicted with a tumor (e.g., a lung cancer). The terms "subject," "human subject," and "patient" can be used interchangeably herein.
[0150] " Administering" refers to the physical introduction of a therapeutic agent to a subject (e.g., a composition or formulation comprising the therapeutic agent, including a single unit dose comprising the composition or formulation), using any of the various methods and delivery systems known to those skilled in the art.
[0151] " Treatment" or "therapy" of a subject refers to any type of intervention or process performed on, or the administration of an active agent to, the subject with the objective of eliminating, reversing, alleviating, ameliorating, inhibiting, reducing, slowing down progression, development, severity or recurrence of a symptom, complication or condition, or biochemical indicia associated with a disease. Response Evaluation Criteria In Solid Tumors (RECIST) is a measure for treatment efficacy and are established rules that define when tumors respond, stabilize, or progress during treatment. RECIST 1.1 is the current guideline to solid tumor measurement and definitions for objective assessment of change in tumor size for use in adult and pediatric cancer clinical trials.
[0152] As used herein, "maintenance therapy" refers to a therapy that is intended to prevent the occurrence or recurrence of tumors.
[0153] As used herein, "a recovery period" is a duration beginning upon the completion of one therapy and ending upon the start of another therapy. In some aspects, the recovery period is a duration sufficient for a subject to recover from adverse events or serious adverse events associated with a therapy.
[0154] As used herein, "effective treatment" refers to treatment producing a beneficial effect, e.g., amelioration of at least one symptom of a disease or disorder. A beneficial effect cantake the form of an improvement over baseline, i.e., an improvement over a measurement or observation made prior to initiation of therapy according to the method. A beneficial effect can also take the form of arresting, slowing, retarding, or stabilizing of a deleterious progression of a marker of solid tumor. Effective treatment can refer to alleviation of at least one symptom of a solid tumor. Such effective treatment can, e.g., reduce patient pain, reduce the size and / or number of lesions, can reduce or prevent metastasis of a tumor, and / or can slow tumor growth.
[0155] The term "effective amount" refers to an amount of an agent that provides the desired biological, therapeutic, and / or prophylactic result. That result can be reduction, amelioration, palliation, lessening, delaying, and / or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. In reference to solid tumors, an effective amount comprises an amount sufficient to cause a tumor to shrink and / or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to delay other unwanted cell proliferation. In some aspects, an effective amount is an amount sufficient to prevent or delay tumor recurrence. An effective amount can be administered in one or more administrations. The effective amount of a drug or composition can: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and can stop cancer cell infiltration into peripheral organs; (iv) inhibit (i.e., slow to some extent and can stop tumor metastasis); (v) inhibit tumor growth; (vi) prevent or delay occurrence and / or recurrence of tumor; and / or (vii) relieve to some extent one or more of the symptoms associated with the cancer. In one example, an "effective amount" is the amount of an anti-LAG-3 antibody and the amount an anti-PD-1 antibody, in combination, clinically proven to affect a significant decrease in cancer or slowing of progression of cancer, such as an advanced solid tumor.
[0156] As used herein, the term "dose" or "dosage" is defined as an amount of a therapeutic agent that can be administered at a given point. The dose or dosage can be an amount sufficient to achieve or at least partially achieve a desired effect, but such a desired effect may not be visible or detectable. A "dose" can comprise a single unit dose or multiple unit doses. In some aspects, the dose comprises a single unit dose. In some aspects, the dose comprises multiple unit doses.
[0157] As used herein, a subcutaneous "unit dose" refers to a single amount of a substance delivered by a subcutaneous administration, e.g., from a single vial, a single auto-injector, a single needle-free injector, a single pen injector, and / or a single syringe. In some aspects, multiple subcutaneous doses are administered to achieve a therapeutically effective dose. When multiple unit doses are administered, individual unit doses can be administered at the same time or sequentially. In some aspects, each unit dose of a therapeutically effective dose is administered onthe same day. Each unit dose can be administered at the same bodily location or at different bodily locations. In some aspects, a first unit dose is administered at a first bodily location, and a second unit dose is administered at a second bodily location. Any bodily locations known in the art to be suitable for subcutaneous delivery can be used in the methods disclosed herein. In some aspects, at least one subcutaneous unit dose of the dose is administered to a bodily location selected from the arm (e.g., the side or back of an upper arm), the abdomen, and the front of the thigh.
[0158] As used herein, the terms "fixed dose," "flat dose," and "flat-fixed dose" are used interchangeably and refer to a dose that is administered to a patient without regard for the weight or body surface area (BSA) of the patient. The fixed or flat dose is therefore not provided as a mg / kg dose, but rather as an absolute amount of the agent (e.g., an amount in pg or mg).
[0159] The use of the term "fixed dose combination" with regard to a composition of the invention means that two or more different antibodies as described herein (e.g., an anti -LAG-3 antibody and an anti-PD-1 antibody) in a single composition are present in the composition in particular (fixed) ratios with each other. In some aspects, the fixed dose is based on the weight (e.g., mg) of the antibodies (e.g., a mg:mg ratio of the inhibitors). In some aspects, the fixed dose is based on the concentration (e.g., mg / ml) of the antibodies (e.g., a mg / mL:mg / mL ratio of the inhibitors). In some aspects, the ratio is at least about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 3:4, about 3:2, about 2:3, or about 4:3 mg first antibody (e.g., an anti-PD-1 antibody) to mg second antibody (e.g., an anti -LAG-3 antibody) or mg / mL first antibody (e.g., an anti-PD-1 antibody) to mg / mL second antibody (e.g., an anti-LAG-3 antibody). For example, a 3: 1 ratio of a first antibody and a second antibody can mean that a vial can contain about 240 mg of the first antibody and about 80 mg of the second antibody, about 480 mg of the first antibody and about 160 mg of the second antibody, about 360 mg of the first antibody and about 120 mg of the second antibody, about 960 mg of the first antibody and about 320 mg of the second antibody, or about 12 mg / ml of the first antibody and about 4 mg / ml of the second antibody. For example, a 1:1 ratio of a first antibody and a second antibody can mean that a vial can contain about 960 mg of the first antibody and about 960 mg of the second antibody, about 720 mg of the first antibody and about 720 mg of the second antibody, about 480 mg of thefirst antibody and about 480 mg of the second antibody, about 360 mg of the first antibody and about 360 mg of the second antibody, about 80 mg / ml of the first antibody and about 80 mg / ml of the second antibody, about 75 mg / ml of the first antibody and about 75 mg / ml of the second antibody, about 72 mg / ml of the first antibody and about 72 mg / ml of the second antibody, about 64 mg / ml of the first antibody and about 64 mg / ml of the second antibody, about 60 mg / ml of the first antibody and about 60 mg / ml of the second antibody, about 52.5 mg / ml of the first antibody and about 52.5 mg / ml of the second antibody, or about 12 mg / ml of the first antibody and about 12 mg / ml of the second antibody. For example, a 3:4 ratio of a first antibody and a second antibody can mean that a vial can contain about 540 mg of the first antibody and about 720 mg of the second antibody, about 64.3 mg / ml of the first antibody and about 85.7 mg / ml of the second antibody, about 60 mg / ml of the first antibody and about 80 mg / ml of the second antibody, about 54 mg / ml of the first antibody and about 72 mg / ml of the second antibody, or about 45 mg / ml of the first antibody and about 60 mg / ml of the second antibody.
[0160] The term "weight based dose" as referred to herein means that a dose that is administered to a patient is calculated based on the weight of the patient.
[0161] " Dosing interval," as used herein, means the amount of time that elapses between multiple doses of a formulation disclosed herein being administered to a subject. Dosing interval can thus be indicated as ranges.
[0162] The term "dosing frequency" as used herein refers to the frequency of administering doses of a formulation disclosed herein in a given time. Dosing frequency can be indicated as the number of doses per a given time, e.g., once a week or once in two weeks, etc.
[0163] The terms "about once a week," "once about every week," "once about every two weeks," or any other similar dosing interval terms as used herein means approximate number, and "about once a week" or "once about every week" can include every seven days ± two days, i.e., every five days to every nine days. The dosing frequency of "about once a week" or "once about every week" thus can be every five days, every six days, every seven days, every eight days, or every nine days. " Once about every three weeks" can include every 21 days ± 3 days, i.e., every 25 days to every 31 days. Similar approximations apply, for example, to once about every two weeks, once about every four weeks, once about every five weeks, once about every six weeks, once about every seven weeks, once about every eight weeks, once about every nine weeks, once about every ten weeks, once about every eleven weeks, and once about every twelve weeks. In some aspects, a dosing interval of once about every six weeks or once about every twelve weeks means that the first dose can be administered any day in the first week, and then the next dose canbe administered any day in the sixth or twelfth week, respectively. In some aspects, a dosing interval of once about every six weeks or once about every twelve weeks means that the first dose is administered on a particular day of the first week (e.g., Monday) and then the next dose is administered on the same day of the sixth or twelfth weeks (i.e., Monday), respectively.
[0164] An "adverse event" (AE) as used herein is any unfavorable and generally unintended or undesirable sign (including an abnormal laboratory finding), symptom, or disease associated with the use of a medical treatment. For example, an adverse event can be associated with activation of the immune system or expansion of immune system cells (e.g., T cells) in response to a treatment. A medical treatment can have one or more associated AEs and each AE can have the same or different level of severity.
[0165] A "cancer" refers a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth divide and grow results in the formation of malignant tumors that invade neighboring tissues and can also metastasize to distant parts of the body through the lymphatic system or bloodstream.
[0166] The term "tumor" as used herein refers to any mass of tissue that results from excessive cell growth or proliferation, either benign (non-cancerous) or malignant (cancerous), including pre-cancerous lesions.
[0167] The term "hematological" as used herein can be used interchangeably with "hematologic," and a hematological cancer can be interchangeably referred to as a hematological malignancy.
[0168] The term "biological sample" as used herein refers to biological material isolated from a subject. The term "biological sample" can be used interchangeably with the term "sample" as referred to herein, such as, for example, in the phrase "a sample of the subject’s tumor." The biological sample can contain any biological material suitable for analysis, for example, by sequencing nucleic acids in the tumor (or circulating tumor cells) and identifying a genomic alteration in the sequenced nucleic acids. The biological sample can be any suitable biological tissue or fluid such as, for example, tumor tissue, blood, blood plasma, and serum. The biological sample can be a test tissue sample (e.g., a tissue sample comprising tumor cells and tumorinfiltrating inflammatory cells). In some aspects, the sample is a tumor tissue biopsy, e.g., a formalin-fixed, paraffin-embedded (FFPE) tumor tissue or a fresh-frozen tumor tissue or the like. In some aspects, the biological sample is a liquid biopsy that, in some aspects, comprises one or more of blood, serum, plasma, circulating tumor cells, exoRNA, ctDNA, and cfDNA.
[0169] By way of example, an "anti-cancer agent" promotes cancer regression in a subject. In some aspects, a therapeutically effective amount of the agent promotes cancer regression to the point of eliminating the cancer. " Promoting cancer regression" means that administering an effective amount of the anti-cancer agent, alone or in combination with another agent, results in a reduction in tumor growth or size, necrosis of the tumor, a decrease in severity of at least one disease symptom, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. In addition, the terms "effective" and "effectiveness" with regard to a treatment includes both pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of the agent to promote cancer regression in the patient. Physiological safety refers to the level of toxicity, or other adverse physiological effects at the cellular, organ and / or organism level (adverse effects) resulting from administration of the agent.
[0170] By way of example for the treatment of tumors, a therapeutically effective amount of an anti-cancer agent can inhibit cell growth or tumor growth by at least about 20%, at least about 40%, at least about 60%, or at least about 80% relative to untreated subjects. In some aspects, tumor regression can be observed and continue for a period of at least about 20 days, at least about 40 days, or at least about 60 days. Notwithstanding these measurements of therapeutic effectiveness, evaluation of immunotherapeutic drugs must also make allowance for immune-related response patterns.
[0171] As used herein, an "immuno-oncology" therapy or an " I-O" or " IO" therapy refers to a therapy that comprises utilizing an immune response to target and treat a tumor in a subject. As such, as used herein, an 1-0 therapy is a type of anti-cancer therapy. In some aspects, an 1-0 therapy comprises administering an antibody to a subject. In some aspects, an 1-0 therapy comprises administering to a subject an immune cell, e.g., a T cell, e.g., a modified T cell, e.g., a T cell modified to express a chimeric antigen receptor or a particular T cell receptor. In some aspects, the 1-0 therapy comprises administering a therapeutic vaccine to a subject. In some aspects, the 1-0 therapy comprises administering a cytokine or a chemokine to a subject. In some aspects, the 1-0 therapy comprises administering an interleukin to a subject. In some aspects, the 1-0 therapy comprises administering an interferon to a subject. In some aspects, the 1-0 therapy comprises administering a colony stimulating factor to a subject.
[0172] An "immune response" refers to the action of a cell of the immune system (for example, T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells and neutrophils) and soluble macromolecules produced by any of these cellsor the liver (including antibodies, cytokines, and complement) that results in selective targeting, binding to, damage to, destruction of, and / or elimination from a vertebrate's body of invading pathogens, cells or tissues infected with pathogens, cancerous or other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues.
[0173] A "tumor-infiltrating inflammatory cell" or "tumor-associated inflammatory cell" is any type of cell that typically participates in an inflammatory response in a subject and which infiltrates tumor tissue. Such cells include tumor-infiltrating lymphocytes (TILs), macrophages, monocytes, eosinophils, histiocytes and dendritic cells.
[0174] The term " FGL-1 positive" or " FGL-1 expression positive," relating to FGL-1 expression, refers to tumor tissue (e.g., a test tissue sample) that is scored as expressing FGL-1 based on the proportion (z.e., percentage) of tumor cells expressing FGL-1 (e.g., greater than or equal to 1% expression).
[0175] " FGL-1 negative" or " FGL-1 expression negative," refers to tumor tissue (e.g., a test tissue sample) that is not scored as expressing FGL-1 (e.g., less than 1% FGL-1 expression in tumor cells).
[0176] The term " LAG-3 positive" or " LAG-3 expression positive," relating to LAG-3 expression, refers to tumor tissue (e.g., a test tissue sample) that is scored as expressing LAG-3 based on the proportion (z.e., percentage) of immune cells (e.g., tumor-infiltrating lymphocytes such as CD8+ T cells) expressing LAG-3 (e.g., greater than or equal to 1% expression) or the proportion (z.e., percentage) of nucleated cells expressing LAG-3 (z.e., the immune cells that express LAG-3 as a proportion of total nucleated cells, e.g., greater than or equal to 1% expression).
[0177] " LAG-3 negative" or " LAG-3 expression negative," refers to tumor tissue (e.g, a test tissue sample) that is not scored as expressing LAG-3 (e.g, less than 1% LAG-3 expression in immune cells and / or nucleated cells).
[0178] The term " PD-1 positive" or " PD-1 expression positive," relating to cell surface PD-L1 expression, refers to tumor tissue (e.g., a test tissue sample) that is scored as expressing PD-L1 based on the tumor proportion score (TPS), which is the proportion (z.e., percentage) of tumor cells expressing PD-L1 (e.g., greater than or equal to 1% expression), or based on the combined positive score (CPS), which is the number of tumor and immune cells (e.g., tumor cells, lymphocytes, and macrophages) in the tumor tissue that express PD-L1 as a percentage of the total number of viable tumor cells (z.e., the number of tumor and immune cells expressing PD-L1 divided by the total number of viable tumor cells and multiplied by 100 (z.e., e.g., greater than or equal to 1%)), or based on the proportion (z.e., percentage) of nucleated cells expressing PD-L1 (z.e., the tumor cellsthat express PD-L1 as a proportion of total nucleated cells, e.g., greater than or equal to 1% expression).
[0179] " PD-1 negative" or " PD-1 expression negative," refers to tumor tissue (e.g., a test tissue sample) that is not scored as expressing PD-1 (e.g., less than 1% PD-1 expression).
[0180] The term " PD-L1 positive" or " PD-L1 expression positive," relating to cell surface PD-L1 expression, refers to tumor tissue (e.g., a test tissue sample) that is scored as expressing PD-L1 based on the proportion (i.e., percentage) of tumor cells expressing PD-L1 (e.g., greater than or equal to 1% expression) or the proportion (i.e., percentage) of nucleated cells expressing PD-L1 (i.e., the tumor cells that express PD-L1 as a proportion of total nucleated cells, e.g., greater than or equal to 1% expression).
[0181] The term " PD-L1 negative" or " PD-L1 expression negative" refers to tumor tissue (e.g., a test tissue sample) that is not scored as expressing PD-L1 (e.g., less than 1% expression).
[0182] Various aspects of the invention are described in further detail in the following subsections.II. Methods of Treating a Tumor
[0183] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody, (ii) an anti -PD-1 antibody, and (iii) an endoglycosidase hydrolase enzyme, wherein the anti-LAG-3 antibody, the anti -PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0184] In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 to the anti-LAG-3 antibody is about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 3:4, about 3:2, about 2:3, or about 4:3.
[0185] In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 antibody to the anti -LAG-3 antibody is about 1:1.
[0186] In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 antibody to the anti -LAG-3 antibody is about 1:2.
[0187] In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 antibody to the anti -LAG-3 antibody is about 2:1.
[0188] In some aspects, the mg:mg or mg / mL:mg / mL ratio of the anti-PD-1 antibody to the anti -LAG-3 antibody is about 3:4.
[0189] In some aspects, the dose of the anti-LAG-3 antibody is about 200 mg to about 1200 mg.
[0190] In some aspects, the dose of the anti-LAG-3 antibody is about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1010 mg, about 1020 mg, about 1030 mg, about 1040 mg, about 1050 mg, about 1060 mg, about 1070 mg, about 1080 mg, about 1090 mg, about 1100 mg, about 1110 mg, about 1120 mg, about 1130 mg, about 1140 mg, about 1150 mg, about 1160 mg, about 1170 mg, about 1180 mg, about 1190 mg, or about 1200 mg.
[0191] In some aspects, the dose of the anti-LAG-3 antibody is about 200 mg.
[0192] In some aspects, the dose of the anti-LAG-3 antibody is about 270 mg.
[0193] In some aspects, the dose of the anti-LAG-3 antibody is about 360 mg.
[0194] In some aspects, the dose of the anti-LAG-3 antibody is about 405 mg.
[0195] In some aspects, the dose of the anti-LAG-3 antibody is about 480 mg.
[0196] In some aspects, the dose of the anti-LAG-3 antibody is about 540 mg.
[0197] In some aspects, the dose of the anti-LAG-3 antibody is about 720 mg.
[0198] In some aspects, the dose of the anti-LAG-3 antibody is about 960 mg.
[0199] In some aspects, the dose of the anti-LAG-3 antibody is about 1200 mg.
[0200] In some aspects, the dose of the anti-PD-1 antibody is about 200 mg to about 1200 mg.
[0201] In some aspects, the dose of the anti-PD-1 antibody is about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1010 mg, about 1020 mg, about 1030 mg, about 1040 mg, about 1050 mg, about 1060 mg, about 1070 mg, about 1080 mg, about 1090 mg, about 1100 mg, about 1110 mg, about 1120 mg, about 1130 mg, about 1140 mg, about 1150 mg, about 1160 mg, about 1170 mg, about 1180 mg, about 1190 mg, or about 1200 mg.
[0202] In some aspects, the dose of the anti-PD-1 antibody is about 200 mg.
[0203] In some aspects, the dose of the anti-PD-1 antibody is about 270 mg.
[0204] In some aspects, the dose of the anti-PD-1 antibody is about 360 mg.
[0205] In some aspects, the dose of the anti-PD-1 antibody is about 405 mg.
[0206] In some aspects, the dose of the anti-PD-1 antibody is about 480 mg.
[0207] In some aspects, the dose of the anti-PD-1 antibody is about 540 mg.
[0208] In some aspects, the dose of the anti-PD-1 antibody is about 720 mg.
[0209] In some aspects, the dose of the anti-PD-1 antibody is about 960 mg.
[0210] In some aspects, the dose of the anti-PD-1 antibody is about 1200 mg.
[0211] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 5,000 international units (IU) to about 32,000 IU.
[0212] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 5,000 IU, about 5100 IU, about 5200 IU, about 5300 IU, about 5400 IU, about 5500 IU, about 5600 IU, about 5700 IU, about 5800 IU, about 5900 IU, about 6000 IU, about 6100 IU, about 6200 IU, about6300 IU, about 6400 IU, about 6500 IU, about 6600 IU, about 6700 IU, about 6800 IU, about 6900 IU, about 7000 IU, about 7100 IU, about 7200 IU, about 7300 IU, about 7400 IU, about 7500 IU, about 7600 IU, about 7700 IU, about 7800 IU, about 7900 IU, about 8000 IU, about 8100 IU, about 8200 IU, about 8300 IU, about 8400 IU, about 8500 IU, about 8600 IU, about 8700 IU, about 8800 IU, about 8900 IU, about 9000 IU, about 9100 IU, about 9200 IU, about 9300 IU, about 9400 IU, about 9500 IU, about 9600 IU, about 9700 IU, about 9800 IU, about 9900 IU, about 10,000 IU, about 10,100 IU, about 10,200 IU, about 10,300 IU, about 10,400 IU, about 10,500 IU, about 10.600 IU, about 10,700 IU, about 10,800 IU, about 10,900 IU, about 11,000 IU, about 11,100 IU, about 11,200 IU, about 11,300 IU, about 11,400 IU, about 11,500 IU, about 11,600 IU, about 11.700 IU, about 11,800 IU, about 11,900 IU, about 12,000 IU, about 12,100 IU, about 12,200 IU, about 12,300 IU, about 12,400 IU, about 12,500 IU, about 12,600 IU, about 12,700 IU, about 12.800 IU, about 12,900 IU, about 13,000 IU, about 13,100 IU, about 13,200 IU, about 13,300 IU, about 13,400 IU, about 13,500 IU, about 13,600 IU, about 13,700 IU, about 13,800 IU, about 13,900 IU, about 14,000 IU, about 14,100 IU, about 14,200 IU, about 14,300 IU, about 14,400 IU, about 14,500 IU, about 14,600 IU, about 14,700 IU, about 14,800 IU, about 14,900 IU, about 15,000 IU, about 15,100 IU, about 15,200 IU, about 15,300 IU, about 15,400 IU, about 15,500 IU, about 15,600 IU, about 15,700 IU, about 15,800 IU, about 15,900 IU, about 16,000 IU, about 16,100 IU, about 16,200 IU, about 16,300 IU, about 16,400 IU, about 16,500 IU, about 16,600 IU, about 16,700 IU, about 16,800 IU, about 16,900 IU, about 17,000 IU, about 17,100 IU, about 17,200 IU, about 17,300 IU, about 17,400 IU, about 17,500 IU, about 17,600 IU, about 17,700 IU, about 17,800 IU, about 17,900 IU, about 18,000 IU, about 18,100 IU, about 18,200 IU, about 18,300 IU, about 18,400 IU, about 18,500 IU, about 18,600 IU, about 18,700 IU, about 18,800 IU, about 18,900 IU, about 19,000 IU, about 19,100 IU, about 19,200 IU, about 19,300 IU, about 19,400 IU, about 19,500 IU, about 19,600 IU, about 19,700 IU, about 19,800 IU, about 19,900 IU, about 20,000 IU, about 20,100 IU, about 20,200 IU, about 20,300 IU, about 20,400 IU, about 20,500 IU, about 20,600 IU, about 20,700 IU, about 20,800 IU, about 20,900 IU, about 21,000 IU, about 21,100 IU, about 21,200 IU, about 21,300 IU, about 21,400 IU, about 21,500 IU, about 21.600 IU, about 21,700 IU, about 21,800 IU, about 21,900 IU, about 22,000 IU, about 22,100 IU, about 22,200 IU, about 22,300 IU, about 22,400 IU, about 22,500 IU, about 22,600 IU, about 22.700 IU, about 22,800 IU, about 22,900 IU, about 23,000 IU, about 23,100 IU, about 23,200 IU, about 23,300 IU, about 23,400 IU, about 23,500 IU, about 23,600 IU, about 23,700 IU, about 23.800 IU, about 23,900 IU, about 24,000 IU, about 24,100 IU, about 24,200 IU, about 24,300 IU, about 24,400 IU, about 24,500 IU, about 24,600 IU, about 24,700 IU, about 24,800 IU, about24,900 IU, about 25,000 IU, about 25,100 IU, about 25,200 IU, about 25,300 IU, about 25,400 IU, about 25,500 IU, about 25,600 IU, about 25,700 IU, about 25,800 IU, about 25,900 IU, about 26,000 IU, about 26,100 IU, about 26,200 IU, about 26,300 IU, about 26,400 IU, about 26,500 IU, about 26,600 IU, about 26,700 IU, about 26,800 IU, about 26,900 IU, about 27,000 IU, about 27,100 IU, about 27,200 IU, about 27,300 IU, about 27,400 IU, about 27,500 IU, about 27,600 IU, about 27,700 IU, about 27,800 IU, about 27,900 IU, about 28,000 IU, about 28,100 IU, about 28,200 IU, about 28,300 IU, about 28,400 IU, about 28,500 IU, about 28,600 IU, about 28,700 IU, about 28,800 IU, about 28,900 IU, about 29,000 IU, about 29,100 IU, about 29,200 IU, about 29,300 IU, about 29,400 IU, about 29,500 IU, about 29,600 IU, about 29,700 IU, about 29,800 IU, about 29,900 IU, about 30,000 IU, about 30,100 IU, about 30,200 IU, about 30,300 IU, about 30,400 IU, about 30,500 IU, about 30,600 IU, about 30,700 IU, about 30,800 IU, about 30,900 IU, about 31,000 IU, about 31,100 IU, about 31,200 IU, about 31,300 IU, about 31,400 IU, about 31,500 IU, about 31,600 IU, about 31,700 IU, about 31,800 IU, about 31,900 IU, or about 32,000 IU.
[0213] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 5,000 IU.
[0214] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 6,000 IU.
[0215] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 7,000 IU.
[0216] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 8,400 IU.
[0217] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 9,000 IU.
[0218] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 9,600 IU.
[0219] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 10,000 IU.
[0220] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 12,000 IU.
[0221] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 12,600 IU.
[0222] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 12,800 IU.
[0223] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 13,500 IU.
[0224] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 14,400 IU.
[0225] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 15,000 IU.
[0226] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 15,500 IU.
[0227] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 16,000 IU.
[0228] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 16,800 IU.
[0229] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 18,000 IU.
[0230] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 19,200 IU.
[0231] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 20,000 IU.
[0232] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 22,500 IU.
[0233] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 24,000 IU.
[0234] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 25,600 IU.
[0235] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 30,000 IU.
[0236] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 32,000 IU.
[0237] In some aspects, the dose of the endoglycosidase hydrolase enzyme is about 2,000 lU / mL.
[0238] In some aspects, the single unit dose comprises a total antibody concentration of about 100 mg / mL or more. In some aspects, the single unit dose comprises a total antibody concentration of about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about 110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL to about 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115 mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120 mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL. In some aspects, the single unit dose comprises a total antibody concentration of about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about 125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL. In some aspects, the single unit dose comprises a total antibody concentration of about 105 mg / mL, about 120 mg / mL, about 126 mg / mL, about 128 mg / mL, about 140 mg / mL, about 144 mg / mL, about 150 mg / mL, or about 160 mg / mL.
[0239] In some aspects, the single unit dose comprises a volume of about 0.001 mL to about 20 mL. In some aspects, the single unit dose comprises a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL, about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL, about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL,about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about 5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL, about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, about 11.5 mL, about 11.6 mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about 13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL, about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2 mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL. In some aspects, the single unit dose comprises a volume of about 8.4 mL, about 9 mL, about 9.6 mL, about 10 mL, about 12 mL, about 12.8 mL, about 15 mL, or about 16 mL.
[0240] In some aspects, the single unit dose is administered once about every 1 week, once about every 2 weeks, once about every 3 weeks, once about every 4 weeks, once about every 5 weeks, once about every 6 weeks, once about every 7 weeks, once about every 8 weeks, once about every 9 weeks, once about every 10 weeks, once about every 11 weeks, or once about every 12 weeks.
[0241] In some aspects, the single unit dose is administered once in 1 week, once in 2 weeks, once in 3 weeks, once in 4 weeks, once in 5 weeks, once in 6 weeks, once in 7 weeks, once in 8 weeks, once in 9 weeks, once in 10 weeks, once in 11 weeks, or once in 12 weeks.
[0242] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg or about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg to about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose. In some aspects the anti-PD-1 antibody is administered to the subject at a dose of about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 800 mg, about 880 mg, about 960 mg, about 1020 mg, about 1080 mg, about 1140 mg, or about 1200 mg.
[0243] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0244] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0245] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 800 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0246] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) anendoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0247] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0248] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0249] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0250] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0251] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0252] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 800 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0253] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0254] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0255] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0256] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0257] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 1200 mg, and (iii) anendoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0258] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0259] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 800 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0260] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0261] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0262] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0263] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
[0264] In some aspects, the single unit dose has a volume of about 9 mL to about 16 mL.
[0265] In some aspects, the single unit dose is administered once about every two, three, or four weeks.
[0266] In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 18,000 IU, about 19,000 IU, about 20,000 IU, about 21,000 IU, about 22,000 IU, about 23,000 IU, about 24,000 IU, about 25,000 IU, about 26,000 IU, about 27,000 IU, about 28,000 IU, about 29,000 IU, about 30,000 IU, about 31,000 IU, or about 32,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 32,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 30,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 26,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 24,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 22,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 20,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 19,000 IU. In some aspects, the endoglycosidase hydrolase enzyme is administered at a dose of about 18,000 IU.
[0267] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 16 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 120 mg / mL.
[0268] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) anendoglycosidase hydrolase enzyme at a dose of about 16,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 8 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 120 mg / mL.
[0269] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 12 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 120 mg / mL.
[0270] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 30,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 15 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 128 mg / mL.
[0271] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 15,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 7.5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 128 mg / mL.
[0272] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 22,500 IU, wherein the anti-LAG-3 antibody,the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 11.25 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 128 mg / mL.
[0273] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 25,600 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 12.8 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0274] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of 12,800 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 6.4 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0275] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 19,200 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 9.6 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0276] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unitdose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 12 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 160 mg / mL.
[0277] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of 12,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 6 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 160 mg / mL.
[0278] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 9 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 160 mg / mL.
[0279] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 16 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0280] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 16,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the singleunit dose has a volume of about 8 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0281] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 12 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0282] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 9 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 160 mg / mL.
[0283] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 9,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 4.5 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 160 mg / mL.
[0284] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 13,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the singleunit dose has a volume of about 6.75 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 160 mg / mL.
[0285] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 19,200 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 9.6 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0286] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 9,600 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 4.8 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0287] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 14,400 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 7.2 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0288] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 20,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the singleunit dose has a volume of about 10 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 144 mg / mL.
[0289] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 10,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 144 mg / mL.
[0290] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 15,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 7.5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 144 mg / mL.
[0291] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 12 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0292] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 12,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the singleunit dose has a volume of about 6 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0293] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 9 mL. In some aspects, the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
[0294] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 16,800 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 8.4 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0295] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 8,400 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 4.2 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0296] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 12,600 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the singleunit dose has a volume of about 6.3 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 150 mg / mL.
[0297] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 9 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 140 mg / mL.
[0298] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 9,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 4.5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 140 mg / mL.
[0299] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 13,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 6.75 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 140 mg / mL.
[0300] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 20,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the singleunit dose has a volume of about 10 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 126 mg / mL.
[0301] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 10,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. In some aspects, the single unit dose has a volume of about 5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 126 mg / mL.
[0302] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 15,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 7.5 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 126 mg / mL.
[0303] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme hyaluronidase at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks. In some aspects, the single unit dose has a volume of about 12 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 105 mg / mL.
[0304] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme hyaluronidase at a dose of about 12,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks. Insome aspects, the single unit dose has a volume of about 6 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 105 mg / mL.
[0305] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme hyaluronidase at a dose of about 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks. In some aspects, the single unit dose has a volume of about 9 mL. In some aspects, the single unit dose comprises a total antibody concentration of about 105 mg / mL.
[0306] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 480 mg to about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg to about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose. In some aspects, the single unit dose is administered to the subject once about every two, three, or four weeks. In some aspects, the anti -LAG-3 antibody is administered at a dose of about 540 mg to about 1200 mg, about 600 mg to about 1200 mg, about 660 mg to about 1200 mg, about 720 mg to about 1200 mg, about 780 mg to about 1200 mg, about 840 mg to about 1200 mg, about 900 mg to about 1200 mg, about 960 mg to about 1200 mg, about 1020 mg to about 1200 mg, about 1080 mg to about 1200 mg, about 1140 mg to about 1200 mg, about 480 mg to about 1140 mg, about 540 mg to about 1140 mg, about 600 mg to about 1140 mg, about 660 mg to about 1140 mg, about 720 mg to about 1140 mg, about 780 mg to about 1140 mg, about 840 mg to about 1140 mg, about 900 mg to about 1140 mg, about 960 mg to about 1140 mg, about 1020 mg to about 1140 mg, about 1080 mg to about 1140 mg, about 480 mg to about 1080 mg, about 540 mg to about 1080 mg, about 600 mg to about 1080 mg, about 660 mg to about 1080 mg, about 720 mg to about 1080 mg, about 780 mg to about 1080 mg, about 840 mg to about 1080 mg, about 900 mg to about 1080 mg, about 960 mg to about 1080 mg, about 1020 mg to about 1080 mg, about 480 mg to about 1020 mg, about 540 mg to about 1020 mg, about 600 mg to about 1020 mg, about 660 mg to about 1020 mg, about 720 mg to about 1020 mg, about 780 mg to about 1020 mg, about 840 mg to about 1020 mg, about 900 mg to about 1020 mg, about 960 mg to about 1020 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about960 mg, about 840 mg to about 960 mg, about 900 mg to about 960 mg, about 480 mg to about 900 mg, about 540 mg to about 900 mg, about 600 mg to about 900 mg, about 660 mg to about 900 mg, about 720 mg to about 900 mg, about 780 mg to about 900 mg, about 840 mg to about 900 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, or about 480 mg to about 540 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, about 960 mg, about 1020 mg, about 1080 mg, about 1140 mg, or about 1200 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 540 mg to about 1200 mg, about 600 mg to about 1200 mg, about 660 mg to about 1200 mg, about 720 mg to about 1200 mg, about 780 mg to about 1200 mg, about 840 mg to about 1200 mg, about 900 mg to about 1200 mg, about 960 mg to about 1200 mg, about 1020 mg to about 1200 mg, about 1080 mg to about 1200 mg, about 1140 mg to about 1200 mg, about 480 mg to about 1140 mg, about 540 mg to about 1140 mg, about 600 mg to about 1140 mg, about 660 mg to about 1140 mg, about 720 mg to about 1140 mg, about 780 mg to about 1140 mg, about 840 mg to about 1140 mg, about 900 mg to about 1140 mg, about 960 mg to about 1140 mg, about 1020 mg to about 1140 mg, about 1080 mg to about 1140 mg, about 480 mg to about 1080 mg, about 540 mg to about 1080 mg, about 600 mg to about 1080 mg, about 660 mg to about 1080 mg, about 720 mg to about 1080 mg, about 780 mg to about 1080 mg, about 840 mg to about 1080 mg, about 900 mg to about 1080 mg, about 960 mg to about 1080 mg, about 1020 mg to about 1080 mg, about 480 mg to about 1020 mg, about 540 mg to about 1020 mg, about 600 mg to about 1020 mg, about 660 mg to about 1020 mg, about 720 mg to about 1020 mg, about 780 mg to about 1020 mg, about 840 mg to about 1020 mg, about 900 mg to about 1020 mg, about 960 mg to about 1020 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 900 mg to about 960 mg, about 480 mg to about 900 mg, about 540 mg to about 900 mg, about 600 mg to about 900 mg, about 660 mg to about 900 mg, about 720 mg to about 900 mg, about 780 mg to about 900 mg, about 840 mg to about 900 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg,about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, or about 480 mg to about 540 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, about 960 mg, about 1020 mg, about 1080 mg, about 1140 mg, or about 1200 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 480 mg and the anti-PD-1 antibody is administered at a dose of about 480 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 540 mg and the anti-PD-1 antibody is administered at a dose of about 540 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 600 mg and the anti-PD-1 antibody is administered at a dose of about 600 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 660 mg and the anti-PD-1 antibody is administered at a dose of about 660 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 720 mg and the anti-PD-1 antibody is administered at a dose of about 720 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 780 mg and the anti-PD-1 antibody is administered at a dose of about 780 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 840 mg and the anti-PD-1 antibody is administered at a dose of about 840 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 900 mg and the anti-PD-1 antibody is administered at a dose of about 900 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 960 mg and the anti-PD-1 antibody is administered at a dose of about 960 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 1020 mg and the anti-PD-1 antibody is administered at a dose of about 1020 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 1080 mg and the anti-PD-1 antibody is administered at a dose of about 1080 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 1140 mg and the anti-PD-1 antibody is administered at a dose of about 1140 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 1200 mg and the anti-PD-1 antibody is administered at a dose of about 1200 mg.
[0307] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 240 mg to about 600 mg, (ii) an anti-PD-1 antibody at a dose of about 240 mgto about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose. In some aspects, the single unit dose is administered to the subject once about every two weeks. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 300 mg to about 600 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 240 mg to about 540 mg, about 300 mg to about 540 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 240 mg to about 480 mg, about 300 mg to about 480 mg, about 360 mg to about 480 mg, about 420 mg to about 480 mg, about 240 mg to about 420 mg, about 300 mg to about 420 mg, about 360 mg to about 420 mg, about 240 mg to about 360 mg, about 300 mg to about 360 mg, or about 240 mg to about 300 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 240 mg, about 300 mg, about 360 mg, about 420 mg, about 480 mg, about 540 mg, or about 600 mg. In some aspects, the anti- PD-1 antibody is administered at a dose of about 300 mg to about 600 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 240 mg to about 540 mg, about 300 mg to about 540 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 240 mg to about 480 mg, about 300 mg to about 480 mg, about 360 mg to about 480 mg, about 420 mg to about 480 mg, about 240 mg to about 420 mg, about 300 mg to about 420 mg, about 360 mg to about 420 mg, about 240 mg to about 360 mg, about 300 mg to about 360 mg, or about 240 mg to about 300 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 240 mg, about 300 mg, about 360 mg, about 420 mg, about 480 mg, about 540 mg, or about 600 mg. In some aspects, the anti -LAG-3 antibody is administered at a dose of about 480 mg and the anti-PD-1 antibody is administered at a dose of about 480 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 540 mg and the anti-PD-1 antibody is administered at a dose of about 540 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 600 mg and the anti-PD-1 antibody is administered at a dose of about 600 mg.
[0308] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg to about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg to about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose. In some aspects, the single unit dose is administeredto the subject once about every three or four weeks. In some aspects, the anti -LAG-3 antibody is administered at a dose of about 420 mg to about 960 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 360 mg to about 840 mg, about 420 mg to about 840 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 360 mg to about 780 mg, about 420 mg to about 780 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 360 mg to about 720 mg, about 420 mg to about 720 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 360 mg to about 660 mg, about 420 mg to about 660 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 360 mg to about 480 mg, about 420 mg to about 480 mg, or about 360 mg to about 420 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 360 mg, about 420 mg, about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, or about 960 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 420 mg to about 960 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 360 mg to about 840 mg, about 420 mg to about 840 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 360 mg to about 780 mg, about 420 mg to about 780 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 360 mg to about 720 mg, about 420 mg to about 720 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 360 mg to about 660 mg, about 420 mg to about 660 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 360 mg to about480 mg, about 420 mg to about 480 mg, or about 360 mg to about 420 mg. In some aspects, the anti-PD-1 antibody is administered at a dose of about 360 mg, about 420 mg, about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, or about 960 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 420 mg and the anti-PD-1 antibody is administered at a dose of about 420 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 480 mg and the anti-PD-1 antibody is administered at a dose of about 480 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 540 mg and the anti-PD-1 antibody is administered at a dose of about 540 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 600 mg and the anti-PD-1 antibody is administered at a dose of about 600 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 660 mg and the anti-PD-1 antibody is administered at a dose of about 660 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 720 mg and the anti-PD-1 antibody is administered at a dose of about 720 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 780 mg and the anti-PD-1 antibody is administered at a dose of about 780 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 840 mg and the anti-PD-1 antibody is administered at a dose of about 840 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 900 mg and the anti-PD-1 antibody is administered at a dose of about 900 mg. In some aspects, the anti-LAG-3 antibody is administered at a dose of about 960 mg and the anti-PD-1 antibody is administered at a dose of about 960 mg.
[0309] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
[0310] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 600 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
[0311] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
[0312] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
[0313] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 900 mg, (ii) an anti-PD-1 antibody at a dose of about 900 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
[0314] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
[0315] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
[0316] The present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) anendoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
[0317] In some aspects, the single unit dose comprises a total antibody concentration of about 100 mg / mL or more. In some aspects, the single unit dose comprises a total antibody concentration of about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about 110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL to about 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115 mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120 mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL. In some aspects, the single unit dose comprises a total antibody concentration of about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about 140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL. In some aspects, the single unit dose comprises a total antibody concentration of about 105 mg / mL, about 120 mg / mL, about 126 mg / mL, about 128 mg / mL, about 140 mg / mL, about 144 mg / mL, about 150 mg / mL, or about 160 mg / mL.
[0318] In some aspects, the single unit dose comprises a volume of about 0.001 mL to about 20 mL. In some aspects, the single unit dose comprises a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL, about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL,about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL, about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about 5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL, about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, about 11.5 mL, about 11.6 mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about 13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL, about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2 mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL. In some aspects, the single unit dose comprises a volume of about 8.4 mL, about 9 mL, about 9.6 mL, about 10 mL, about 12 mL, about 12.8 mL, about 15 mL, or about 16 mL.
[0319] In some aspects, the single unit dose comprises about 80 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dosecomprises a volume of about 12 mL. In some aspects, the single unit dose comprises a volume of about 9 mL.
[0320] In some aspects, the single unit dose comprises about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose comprises a volume of about 12.8 mL. In some aspects, the single unit dose comprises a volume of about 9.6 mL.
[0321] In some aspects, the single unit dose comprises about 72 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose comprises a volume of about 10 mL.
[0322] In some aspects, the single unit dose comprises about 64 mg / mL of the anti-PD-1 antibody and about 64 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose comprises a volume of about 15 mL.
[0323] In some aspects, the single unit dose comprises about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose has a volume of about 16 mL. In some aspects, the single unit dose has a volume of about 12 mL.
[0324] In some aspects, the single unit dose comprises about 64.3 mg / mL of the anti-PD-1 antibody and about 85.7 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose has a volume of about 8.4 mL.
[0325] In some aspects, the single unit dose comprises about 60 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose has a volume of about 9 mL.
[0326] In some aspects, the single unit dose comprises about 54 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose has a volume of about 10 mL.
[0327] In some aspects, the single unit dose comprises about 45 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody. In some aspects, the single unit dose has a volume of about 12 mL.
[0328] In some aspects, the dose of the anti-LAG-3 antibody, anti-PD-1 antibody, and / or endoglycosidase hydrolase enzyme is a flat dose.
[0329] In some aspects, the single unit dose is subcutaneously administered to the subject with a syringe comprising the single unit dose. In some aspects, the syringe is a pre-filled syringe comprising the single unit dose ( / .<., a syringe pre-filled with the unit dose). A pre-filled syringe,for example, does not require filling at the time of use and instead has been previously filled with the single unit dose. In some aspects, the syringe further comprises a plunger.
[0330] In some aspects, the single unit dose is subcutaneously administered to the subject with an auto-injector comprising the single unit dose. In some aspects, the auto-injector comprises a needle shield and a needle. In some aspects, the needle shield is activated by pressure on an injection site, wherein the needle is engaged by the needle shield for injection of the single unit dose.
[0331] In some aspects, the single unit dose is subcutaneously administered to the subject with a wearable pump or a wearable device comprising the single unit dose. In some aspects, the wearable pump comprises a patch pump.
[0332] In some aspects, the single unit dose is subcutaneously administered to the subject with a pen injector comprising the single unit dose. In some aspects, the pen injector comprises a push button and a needle, wherein the needle is engaged by activation of the push-button for injection of the single unit dose.
[0333] In some aspects, the single unit dose is subcutaneously administered to the subject with a needle-free injector comprising the single unit dose.
[0334] In some aspects, the single unit dose is administered within about 10 minutes or less.
[0335] In some aspects, the single unit dose is administered by subcutaneous injection within about 2 minutes to about 10 minutes, about 2 minutes to about 9 minutes, about 2 minutes to about 8 minutes, about 2 minutes to about 7 minutes, about 2 minutes to about 6 minutes, about 2 minutes to about 5 minutes, about 2 minutes to about 4 minutes, about 2 minutes to about 3 minutes, about 3 minutes to about 10 minutes, about 3 minutes to about 9 minutes, about 3 minutes to about 8 minutes, about 3 minutes to about 7 minutes, about 3 minutes to about 6 minutes, about 3 minutes to about 5 minutes, about 3 minutes to about 4 minutes, about 4 minutes to about 10 minutes, about 4 minutes to about 9 minutes, about 4 minutes to about 8 minutes, about 4 minutes to about 7 minutes, about 4 minutes to about 6 minutes, about 4 minutes to about 5 minutes, about 5 minutes to about 10 minutes, about 5 minutes to about 9 minutes, about 5 minutes to about 8 minutes, about 5 minutes to about 7 minutes, or about 5 minutes to about 6 minutes.
[0336] In some aspects, the single unit dose is administered within about 5 minutes to about 7 minutes. In some aspects, the single unit dose is administered within about 3 minutes to about 5 minutes.
[0337] In some aspects, each subcutaneous administration of the single unit dose is to the same bodily location. As used herein, where subcutaneous unit doses are administered to the same bodily location, the subcutaneous doses can be administered to the same site or to a nearby site within the same bodily location.
[0338] In some aspects, each subcutaneous administration of the single unit dose is to a different bodily location as compared to the next subcutaneous administration.
[0339] In some aspects, the bodily location is the subj ect’ s abdomen, left thigh, right thigh, left arm, or right arm. In such aspects, “right” and “left” are defined from the subject’s perspective.
[0340] In some aspects, the minimum serum concentration at day 28 (CminD28), the average serum concentration at day 28 (CavgD28), the minimum serum concentration at steady state (CminSS), and / or the average serum concentration at steady state (CavgSS) of the anti-PD-1 antibody in the subject (e.g., in a subject to whom 720 mg or more of the anti-PD-1 antibody has been administered once about every three or four weeks) is about equal to or greater than the geometric mean CminD28, CavgD28, CminSS, and / or CavgSS, respectively, of nivolumab in a population of subjects in which 480 mg of nivolumab is intravenously administered once about every four weeks to each subject in the population.
[0341] In some aspects, the CminD28, CavgD28, CminSS, and / or CavgSS of the anti-LAG-3 antibody in the subject (e.g, in a subject to whom 720 mg or more of the anti -LAG-3 antibody has been administered once about every three or four weeks) is about equal to or greater than the geometric mean CminD28, CavgD28, CminSS, and / or CavgSS, respectively, of relatlimab in a population of subjects in which 480 mg of relatlimab is intravenously administered once about every four weeks to each subject in the population.
[0342] In some aspects, the CminD28, CavgD28, CminSS, and / or CavgSS of the anti-LAG-3 antibody in the subject (e.g, in a subject to whom 540 mg or more of the anti -LAG-3 antibody has been administered once about every three weeks) is about equal to or greater than the geometric mean CminD28, CavgD28, CminSS, and / or CavgSS, respectively, of relatlimab in a population of subjects in which 360 mg of relatlimab is intravenously administered once about every three weeks to each subject in the population.
[0343] In some aspects, following subcutaneous administration to a subject of a single unit dose as disclosed herein comprising 720 mg, 800 mg, or 900 mg of nivolumab, the Cmaxl of nivolumab (z.e., the maximum serum concentration of nivolumab after the first dose of the single unit dose) in the subject is within the percentage coefficient of variation (%CV) of the geometric mean Cmaxl of nivolumab in a population of subjects in which the same single unit dose issubcutaneously administered to each subject in the population. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean Cmaxl is about 55 pg / mL to about 75 pg / mL, about 60 pg / mL to about 70 pg / mL, or about 60 pg / mL to about 65 pg / mL, and the %CV is about 30% to about 40%. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean Cmaxl is about 63.5 pg / mL and the %CV is about 36.1%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean Cmaxl is about 60 pg / mL to about 80 pg / mL or about 65 pg / mL to about 75 pg / mL, and the %CV is about 30% to about 40%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean Cmaxl is about 70.5 pg / mL and the %CV is about 36.1%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean Cmaxl is about 75 pg / mL to about 95 pg / mL or about 80 pg / mL to about 90 pg / mL, and the %CV is about 30% to about 40%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean Cmaxl is about 84.6 pg / mL and the %CV is about 36.1%.
[0344] In some aspects, following subcutaneous administration to a subject of a single unit dose as disclosed herein comprising 720 mg, 800 mg, or 960 mg of nivolumab, the minimum serum concentration at day 28 of nivolumab (CminD28) in the subject is within the %CV of the geometric mean CminD28 of nivolumab in a population of subjects in which the same single unit dose is subcutaneously administered to each subject in the population once about every four weeks. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean CminD28 is about 20 pg / mL to about 40 pg / mL or about 25 pg / mL to about 35 pg / mL, and the %CV is about 35% to about 45%. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean CminD28 is about 27.7 pg / mL and the %CV is about 41.4%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean CminD28 is about 20 pg / mL to about 40 pg / mL or about 25 pg / mL to about 35 pg / mL, and the %CV is about 35% to about 45%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean CminD28 is about 30.8 pg / mL and the %CV is about 41.4%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean CminD28 is about 30 pg / mL to about 50 pg / mL or about 35 pg / mL to about 45 pg / mL, and the %CV is about 35% to about 45%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean CminD28 is about 37 pg / mL and the %CV is about 41.4%.
[0345] In some aspects, following subcutaneous administration to a subject of a single unit dose as disclosed herein comprising 720 mg, 800 mg, or 960 mg of nivolumab, the average serum concentration at day 28 of nivolumab (CavgD28) in the subject is within the %CV of the geometricmean CavgD28 of nivolumab in a population of subjects in which the same single unit dose is subcutaneously administered to each subject in the population once about every four weeks. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean CavgD28 is about 35 pg / mL to about 55 pg / mL or about 40 pg / mL to about 50 pg / mL, and the %CV is about 30% to about 40%. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean CavgD28 is about 44.5 pg / mL and the %CV is about 33.9%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean CavgD28 is about 40 pg / mL to about 60 pg / mL or about 45 pg / mL to about 55 pg / mL, and the %CV is about 30% to about 40%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean CavgD28 is about 49.4 pg / mL and the %CV is about 33.9%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean CavgD28 is about 50 pg / mL to about 70 pg / mL or about 55 pg / mL to about 65 pg / mL, and the %CV is about 30% to about 40%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean CavgD28 is about 59.3 pg / mL and the %CV is about 33.9%.
[0346] In some aspects, following subcutaneous administration to a subject of a single unit dose as disclosed herein comprising 720 mg, 800 mg, or 960 mg of nivolumab, the maximum serum concentration at steady state of nivolumab (CmaxSS) in the subject is within the %CV of the geometric mean CmaxSS of nivolumab in a population of subjects in which the same single unit dose is subcutaneously administered to each subject in the population once about every four weeks. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean CmaxSS is about 120 pg / mL to about 140 pg / mL or about 125 pg / mL to about 135 pg / mL, and the %CV is about 35% to about 45%. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean CmaxSS is about 129 pg / mL and the %CV is about 42.8%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean CmaxSS is about 135 pg / mL to about 155 pg / mL or about 140 pg / mL to about 150 pg / mL, and the %CV is about 35% to about 45%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean CmaxSS is about 143 pg / mL and the %CV is about 42.8%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean CmaxSS is about 160 pg / mL to about 180 pg / mL or about 165 pg / mL to about 175 pg / mL and the %CV is about 35% to about 45%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean CmaxSS is about 171 pg / mL and the %CV is about 42.8%.
[0347] In some aspects, following subcutaneous administration to a subject of a single unit dose as disclosed herein comprising 720 mg, 800 mg, or 960 mg of nivolumab, the minimum serumconcentration at steady state of nivolumab (CminSS) in the subject is within the %CV of the geometric mean CminSS of nivolumab in a population of subjects in which the same single unit dose is subcutaneously administered to each subject in the population once about every four weeks. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean CminSS is about 55 pg / mL to about 75 pg / mL or about 60 pg / mL to about 70 pg / mL, and the %CV is about 55% to about 65%. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean CminSS is about 66.6 pg / mL and the %CV is about 61.5%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean CminSS is about 65 pg / mL to about 85 pg / mL or about 70 pg / mL to about 80 pg / mL, and the %CV is about 55% to about 65%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean CminSS is about 74 pg / mL and the %CV is about 61.5%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean CminSS is about 80 pg / mL to about 100 pg / mL or about 85 pg / mL to about 95 pg / mL, and the %CV is about 55% to about 65%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean CminSS is about 88.8 pg / mL and the %CV is about 61.5%.
[0348] In some aspects, following subcutaneous administration to a subject of a single unit dose as disclosed herein comprising 720 mg, 800 mg, or 960 mg of nivolumab, the average serum concentration at steady state of nivolumab (CavgSS) in the subject is within the %CV of the geometric mean CavgSS of nivolumab in a population of subjects in which the same single unit dose is subcutaneously administered to each subject in the population once about every four weeks. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean CavgSS is about 90 pg / mL to about 110 pg / mL or about 95 pg / mL to about 105 pg / mL, and the %CV is about 45% to about 55%. In some aspects for a single unit dose comprising 720 mg of nivolumab, the geometric mean CavgSS is about 99.1 pg / mL and the %CV is about 48.8%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean CavgSS is about 100 pg / mL to about 120 pg / mL or about 105 pg / mL to about 115 pg / mL, and the %CV is about 45% to about 55%. In some aspects for a single unit dose comprising 800 mg of nivolumab, the geometric mean CavgSS is about 110 pg / mL and the %CV is about 48.8%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean CavgSS is about 120 pg / mL to about 140 pg / mL or about 125 pg / mL to about 135 pg / mL, and the %CV is about 45% to about 55%. In some aspects for a single unit dose comprising 960 mg of nivolumab, the geometric mean CavgSS is about 132 pg / mL and the %CV is about 48.8%.
[0349] In some aspects, following subcutaneous administration to a subject of a single unit dose as disclosed herein comprising 720 mg, 840 mg, or 960 mg of relatlimab, wherein the relatlimab comprises a bioavailability of about 58%, the CminD28 in the subject is within the %CV of the geometric mean CminD28 of relatlimab in a population of subjects in which the same single unit dose is subcutaneously administered to each subject in the population once about every four weeks. In some aspects for a single unit dose comprising 720 mg of relatlimab, the geometric mean CminD28 is about 15 pg / mL to about 35 pg / mL or about 20 pg / mL to about 30 pg / mL, and the %CV is about 35% to about 45%. In some aspects for a single unit dose comprising 720 mg of relatlimab, the geometric mean CminD28 is about 23 pg / mL and the %CV is about 38.8%. In some aspects for a single unit dose comprising 840 mg of relatlimab, the geometric mean CminD28 is about 20 pg / mL to about 40 pg / mL or about 25 pg / mL to about 35 pg / mL, and the %CV is about 35% to about 45%. In some aspects for a single unit dose comprising 840 mg of relatlimab, the geometric mean CminD28 is about 27.8 pg / mL and the %CV is about 37.9%. In some aspects for a single unit dose comprising 960 mg of relatlimab, the geometric mean CminD28 is about 20 pg / mL to about 40 pg / mL or about 25 pg / mL to about 35 pg / mL, and the %CV is about 35% to about 45%. In some aspects for a single unit dose comprising 960 mg of relatlimab, the geometric mean CminD28 is about 32.7 pg / mL and the %CV is about 37.2%.
[0350] In some aspects, following subcutaneous administration to a subject of a single unit dose as disclosed herein comprising 720 mg, 840 mg, or 960 mg of relatlimab, wherein the relatlimab comprises a bioavailability of about 58%, the CavgD28 in the subject is within the %CV of the geometric mean CavgD28 of relatlimab in a population of subjects in which the same single unit dose is subcutaneously administered to each subject in the population once about every four weeks. In some aspects for a single unit dose comprising 720 mg of relatlimab, the geometric mean CavgD28 is about 30 pg / mL to about 50 pg / mL or about 35 pg / mL to about 45 pg / mL, and the %CV is about 20% to about 30%. In some aspects for a single unit dose comprising 720 mg of relatlimab, the geometric mean CavgD28 is about 37.2 pg / mL and the %CV is about 26%. In some aspects for a single unit dose comprising 840 mg of relatlimab, the geometric mean CminD28 is about 35 pg / mL to about 55 pg / mL or about 40 pg / mL to about 50 pg / mL, and the %CV is about 20% to about 30%. In some aspects for a single unit dose comprising 840 mg of relatlimab, the geometric mean CavgD28 is about 43.9 pg / mL and the %CV is about 25.8%. In some aspects for a single unit dose comprising 960 mg of relatlimab, the geometric mean CminD28 is about 40 pg / mL to about 60 pg / mL or about 45 pg / mL to about 55 pg / mL, and the %CV is about 20% toabout 30%. In some aspects for a single unit dose comprising 960 mg of relatlimab, the geometric mean CavgD28 is about 50.7 pg / mL and the %CV is about 25.7%.
[0351] In some aspects, following subcutaneous administration to a subject of a single unit dose as disclosed herein comprising 720 mg, 840 mg, or 960 mg of relatlimab, wherein the relatlimab comprises a bioavailability of about 58%, the CminSS in the subject is within the %CV of the geometric mean CminSS of relatlimab in a population of subjects in which the same single unit dose is subcutaneously administered to each subject in the population once about every four weeks. In some aspects for a single unit dose comprising 720 mg of relatlimab, the geometric mean CminSS is about 45 pg / mL to about 65 pg / mL or about 50 pg / mL to about 60 pg / mL, and the %CV is about 50% to about 60%. In some aspects for a single unit dose comprising 720 mg of relatlimab, the geometric mean CminSS is about 55.3 pg / mL and the %CV is about 55.2%. In some aspects for a single unit dose comprising 840 mg of relatlimab, the geometric mean CminSS is about 55 pg / mL to about 75 pg / mL or about 60 pg / mL to about 70 pg / mL, and the %CV is about 50% to about 60%. In some aspects for a single unit dose comprising 840 mg of relatlimab, the geometric mean CminSS is about 66.7 pg / mL and the %CV is about 54.4%. In some aspects for a single unit dose comprising 960 mg of relatlimab, the geometric mean CminSS is about 70 pg / mL to about 90 pg / mL or about 75 pg / mL to about 85 pg / mL, and the %CV is about 50% to about 60%. In some aspects for a single unit dose comprising 960 mg of relatlimab, the geometric mean CminSS is about 78 pg / mL and the %CV is about 53.9%
[0352] In some aspects, following subcutaneous administration to a subject of a single unit dose as disclosed herein comprising 720 mg, 840 mg, or 960 mg of relatlimab, wherein the relatlimab comprises a bioavailability of about 58%, the CavgSS in the subject is within the %CV of the geometric mean CavgSS of relatlimab in a population of subjects in which the same single unit dose is subcutaneously administered to each subject in the population once about every four weeks. In some aspects for a single unit dose comprising 720 mg of relatlimab, the geometric mean CavgSS is about 70 pg / mL to about 90 pg / mL or about 75 pg / mL to about 85 pg / mL, and the %CV is about 40% to about 50%. In some aspects for a single unit dose comprising 720 mg of relatlimab, the geometric mean CavgSS is about 81.9 pg / mL and the %CV is about 43.8%. In some aspects for a single unit dose comprising 840 mg of relatlimab, the geometric mean CavgSS is about 90 pg / mL to about 110 pg / mL or about 95 pg / mL to about 105 pg / mL, and the %CV is about 40% to about 50%. In some aspects for a single unit dose comprising 840 mg of relatlimab, the geometric mean CavgSS is about 97.6 pg / mL and the %CV is about 43.5%. In some aspects for a single unit dose comprising 960 mg of relatlimab, the geometric mean CavgSS is about 105 pg / mL to about125 pg / mL or about 110 pg / mL to about 120 pg / mL, and the %CV is about 40% to about 50%. In some aspects for a single unit dose comprising 960 mg of relatlimab, the geometric mean CavgSS is about 113 pg / mL and the %CV is about 43.2%.ILA. Anti-LAG-3 Antibodies
[0353] An exemplary LAG-3 antibody useful in the present disclosure is 25F7 (described in U. S. Publ. No. 2011 / 0150892). An additional exemplary LAG-3 antibody useful in the present disclosure is BMS-986016 (relatlimab). In some aspects, an anti -LAG-3 antibody useful in the present disclosure cross-competes with 25F7 or BMS-986016. In some aspects, an anti -LAG-3 antibody useful in the present disclosure binds to the same epitope as 25F7 or BMS-986016. In some aspects, an anti-LAG-3 antibody comprises six CDRs of 25F7 or BMS-986016.
[0354] Other art-recognized anti-LAG-3 antibodies that can be used in the methods of the disclosure include IMP731 (H5L7BW) described in US 2011 / 007023, MK-4280 (28G-10, favezelimab) described in WO2016028672 and U. S. Publication No. 2020 / 0055938, REGN3767 (fianlimab) described in Burova E, etal., J. Immunother. Cancer (2016); 4(Supp. 1): P195 and U. S. Patent No. 10,358,495, humanized BAP050 described in WO2017 / 019894, GSK2831781, IMP-701 (LAG525; ieramilimab) described in U. S. Patent No. 10,711,060 and U. S. Publ. No.2020 / 0172617, aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (previously XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, AGEN1746, RO7247669, INCAGN02385, IBL110, EMB-02, IBL323, LBL-007, and ABL501. These and other anti-LAG-3 antibodies useful in the claimed invention can be found in, for example: US 10,188,730, WO 2016 / 028672, WO 2017 / 106129, WO2017 / 062888, W02009 / 044273, WO2018 / 069500, WO2016 / 126858, WO2014 / 179664, WO2016 / 200782, W02015 / 200119, WO2017 / 019846, WO2017 / 198741, WO2017 / 220555, WO2017 / 220569, WO2018 / 071500, W02017 / 015560, WO2017 / 025498, WO2017 / 087589, WO2017 / 087901, W02018 / 083087, WO2017 / 149143, WO2017 / 219995, US2017 / 0260271, WO2017 / 086367, WO2017 / 086419, WO2018 / 034227, WO2018 / 185046, WO2018 / 185043, WO2018 / 217940, W019 / 011306, WO2018 / 208868, W02014 / 140180, WO2018 / 201096, WO2018 / 204374, and W02019 / 018730. The contents of each of these references are incorporated by reference in their entirety.
[0355] Anti-LAG-3 antibodies that can be used in the methods of the disclosure also include isolated antibodies that bind specifically to human LAG-3 and cross-compete for binding to human LAG-3 with any anti-LAG-3 antibody disclosed herein, e.g., relatlimab. In some aspects,the anti-LAG-3 antibody binds the same epitope as any of the anti-LAG-3 antibodies described herein, e.g., relatlimab.
[0356] In some aspects, the antibodies that cross-compete for binding to human LAG-3 with, or bind to the same epitope region as, any anti-LAG-3 antibody disclosed herein, e.g., relatlimab, are monoclonal antibodies. For administration to human subjects, these crosscompeting antibodies are chimeric antibodies, engineered antibodies, or humanized or human antibodies. Such chimeric, engineered, humanized or human monoclonal antibodies can be prepared and isolated by methods well known in the art.
[0357] The ability of antibodies to cross-compete for binding to an antigen indicates that the antibodies bind to the same epitope region of the antigen and sterically hinder the binding of other cross-competing antibodies to that particular epitope region. These cross-competing antibodies are expected to have functional properties very similar those of the reference antibody, e.g., relatlimab, by virtue of their binding to the same epitope region. Cross-competing antibodies can be readily identified based on their ability to cross-compete in standard binding assays such as BIACORE analysis, ELISA assays or flow cytometry (see, e.g., WO 2013 / 173223).
[0358] Anti-LAG-3 antibodies that can be used in the methods of the disclosure also include antigen binding portions of any of the above full-length antibodies. It has been amply demonstrated that the antigen binding function of an antibody can be performed by fragments of a full-length antibody.
[0359] In some aspects, the anti-LAG-3 antibody comprises a full-length antibody.
[0360] In some aspects, the anti-LAG-3 antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody. In some aspects, the multispecific antibody comprises a dual-affinity re-targeting antibody (DART), dual variable domain immunoglobulin (DVD-Ig), or a bispecific antibody.
[0361] In some aspects, the anti-LAG-3 antibody comprises a multispecific antibody, e.g., a bispecific antibody, that specifically binds (i) LAG-3 and (ii) a second antigen. In some aspects, the antibody comprises a multispecific antibody, e.g., a bispecific antibody, that specifically binds two different antigens (e.g., LAG-3 and PD-1).
[0362] In some aspects, the anti-LAG-3 antibody comprises a trispecific antibody. In some aspects, the antibody specifically binds (i) LAG-3, (ii) a second antigen, and (iii) a third antigen. In some aspects, the second antigen and third antigen are the same. In some aspects, the second antigen and third antigen are different (e.g., PD-1 and CD3, respectively).
[0363] In some aspects, the antigen binding moieties in a bispecific or a trispecific antibody are scFVs, e.g., the scFv of relatlimab for a bispecific or trispecific antibody that specifically binds LAG-3.
[0364] In some aspects, the anti-LAG-3 antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.
[0365] In some aspects, the anti-LAG-3 antibody comprises BMS-986016 (relatlimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, ieramilimab), aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBL110, EMB-02, IBL 323, LBL-007, ABL501, or an antigen binding portion thereof.
[0366] In some aspects, the anti-LAG-3 antibody comprises relatlimab, or an antigen binding portion thereof.
[0367] In some aspects, the anti-LAG-3 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of relatlimab.
[0368] In some aspects, the anti-LAG-3 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively; (d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:l and 2, respectively; or (e) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively.
[0369] In some aspects, the anti-LAG-3 antibody comprises MGD013 (tebotelimab), which is a bispecific PD-1 x LAG-3 DART.
[0370] In some aspects, the anti-LAG-3 antibody comprises the heavy and light chain variable region CDRs and / or the heavy and light chain variable regions of tebotelimab.
[0371] In some aspects, the anti-LAG-3 antibody comprises REGN3767 (fianlimab).
[0372] In some aspects, the anti-LAG-3 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of fianlimab.
[0373] In some aspects, the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:25, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:26. In some aspects, the anti-LAG-3 antibody comprises (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:27; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:28; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:29; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:30; (e) a light chain variable region CDR2 comprising the amino acid sequence DAS; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:32. In some aspects, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:25 and 26, respectively. In some aspects, the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:23 and 24, respectively.
[0374] In some aspects, the anti-LAG-3 antibody comprises LAG525 (ieramilimab).
[0375] In some aspects, the anti-LAG-3 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of ieramilimab.
[0376] In some aspects, the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:47, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:49. In some aspects, the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:48, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:50. In some aspects, the anti-LAG-3 antibody comprises (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:51; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 52; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:53; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:54; (e) a light chain variableregion CDR2 comprising the amino acid sequence set forth in SEQ ID NO:55; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:56. In some aspects, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:47 and 49, respectively. In some aspects, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:48 and 50, respectively. In some aspects, the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:43 and 45, respectively. In some aspects, the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:44 and 46, respectively.
[0377] In some aspects, the anti-LAG-3 antibody comprises MK4280 (favezelimab).
[0378] In some aspects, the anti-LAG-3 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of favezelimab.
[0379] In some aspects, the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 69, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:70. In some aspects, the anti-LAG-3 antibody comprises (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:71; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:72; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:73; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:74; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:75; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:76. In some aspects, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:69 and 70, respectively.II. B. Anti-PD-1 Antibodies
[0380] Various human monoclonal antibodies that bind specifically to PD-1 with high affinity have been disclosed in U. S. Patent No. 8,008,449. Anti-PD-1 human antibodies disclosed in U. S. Patent No. 8,008,449 have been demonstrated to exhibit one or more of the following characteristics: (a) bind to human PD-1 with a KD of 1 x 10'7M or less, as determined by surfaceplasmon resonance using a BIACORE biosensor system; (b) do not substantially bind to human CD28, CTLA-4 or ICOS; (c) increase T-cell proliferation in a Mixed Lymphocyte Reaction (MLR) assay; (d) increase interferon-y production in an MLR assay; (e) increase IL-2 secretion in an MLR assay; (f) bind to human PD-1 and cynomolgus monkey PD-1; (g) inhibit the binding of PD-L1 and / or PD-L2 to PD-1; (h) stimulate antigen-specific memory responses; (i) stimulate antibody responses; and (j) inhibit tumor cell growth in vivo. Anti -PD-1 antibodies usable in the present disclosure include monoclonal antibodies that bind specifically to human PD-1 and exhibit at least one, in some aspects, at least five, of the preceding characteristics.
[0381] Other anti-PD-1 monoclonal antibodies have been described in, for example, U. S.Patent Nos. 6,808,710, 7,488,802, 8,168,757 and 8,354,509, US Publication No. 2016 / 0272708, and PCT Publication Nos. WO 2012 / 145493, WO 2008 / 156712, WO 2015 / 112900, WO 2012 / 145493, WO 2015 / 112800, WO 2014 / 206107, WO 2015 / 35606, WO 2015 / 085847, WO 2014 / 179664, WO 2017 / 020291, WO 2017 / 020858, WO 2016 / 197367, WO 2017 / 024515, WO 2017 / 025051, WO 2017 / 123557, WO 2016 / 106159, WO 2014 / 194302, WO 2017 / 040790, WO 2017 / 133540, WO 2017 / 132827, WO 2017 / 024465, WO 2017 / 025016, WO 2017 / 106061, WO 2017 / 19846, WO 2017 / 024465, WO 2017 / 025016, WO 2017 / 132825, and WO 2017 / 133540 each of which is incorporated by reference in its entirety.
[0382] In some aspects, the anti-PD-1 antibody comprises a full-length antibody.
[0383] In some aspects, the anti-PD-1 antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody. In some aspects, the multispecific antibody comprises a dual-affinity re-targeting antibody (DART), a dual variable domain immunoglobulin (DVD-Ig), or a bispecific antibody.
[0384] In some aspects, the anti-PD-1 antibody comprises a multispecific antibody, e.g., a bispecific antibody, that specifically binds (i) PD-1 and (ii) a second antigen (e.g., LAG-3, CD3, or TIGIT).
[0385] In some aspects, the anti-PD-1 antibody comprises a trispecific antibody. In some aspects, the trispecific antibody specifically binds (i) PD-1, (ii) a second antigen, and (iii) a third antigen. In some aspects, the second antigen and third antigen are the same. In some aspects, the second antigen and third antigen are different.
[0386] In some aspects, the antigen binding moieties in a bispecific or a trispecific antibody are scFVs, e.g., the scFv of nivolumab for a bispecific or trispecific antibody that specifically binds PD-1.
[0387] In some aspects, the anti-PD-1 antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.
[0388] In some aspects, the anti-PD-1 antibody comprises nivolumab (also known as OPDIVO, 5C4, BMS-936558, MDX-1106, and ONO-4538), pembrolizumab (Merck; also known as KEYTRUDA, lambrolizumab, and MK-3475; see WO2008 / 156712), PDR001 (Novartis; also known as spartalizumab; see WO 2015 / 112900 and U. S. Patent No. 9,683,048), MEDI-0680 (AstraZeneca; also known as AMP-514; see WO 2012 / 145493), TSR-042 (Tesaro Biopharmaceutical; also known as ANB011 or dostarlimab; see WO2014 / 179664), cemiplimab (Regeneron; also known as LIBTAYO or REGN-2810; see WO 2015 / 112800 and U. S. Patent No.9,987,500), JS001 (TAIZHOU JUNSHI PHARMA; also known as toripalimab; see Si-Yang Liu et al., J. Hematol. Oncol. 70:136 (2017)), PF-06801591 (Pfizer; also known as sasanlimab), BGB-A317 (Beigene; also known as tislelizumab; see WO 2015 / 35606 and US 2015 / 0079109), BI 754091 (Boehringer Ingelheim; see Zettl M et al., Cancer. Res. (2018);78(13 Suppl): Abstract 4558), INCSHR1210 (Jiangsu Hengrui Medicine; also known as SHR-1210 or camrelizumab; see WO 2015 / 085847; Si-Yang Liu et al., J. Hematol. Oncol. 70:136 (2017)), GLS-010 (Wuxi / Harbin Gloria Pharmaceuticals; also known as WBP3055; see Si-Yang Liu et al., J. Hematol. Oncol.70:136 (2017)), AM-0001 (Anno), STI-1110 (Sorrento Therapeutics; see WO 2014 / 194302), AGEN2034 (Agenus; see WO 2017 / 040790), MGA012 (Macrogenics, see WO 2017 / 19846), BCD-100 (Biocad; Kaplon et al., mAbs 70(2 / 183-203 (2018), IBI308 (Innovent; also known as sintilimab; see WO 2017 / 024465, WO 2017 / 025016, WO 2017 / 132825, and WO 2017 / 133540);; US 2016 / 0159905); SSI-361 (Lyvgen Biopharma Holdings Limited, US 2018 / 0346569), or an antigen binding portion thereof.
[0389] In some aspects, the anti-PD-1 antibody comprises nivolumab, or an antigen binding portion thereof. Nivolumab is a fully human IgG4 (S228P) PD-1 immune checkpoint inhibitor antibody that selectively prevents interaction with PD-1 ligands (PD-L1 and PD-L2), thereby blocking the down-regulation of antitumor T-cell functions (U. S. Patent No. 8,008,449; Wang et al., 2014 Cancer Immunol Res. 2(5 / 846-56).
[0390] In some aspects, the anti-PD-1 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of nivolumab.
[0391] In some aspects, the anti-PD-1 antibody comprises: (a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ IDNO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14; (b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, respectively; (c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs: 13 and 14, respectively; or (d) heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively.
[0392] In some aspects, the anti-PD-1 antibody comprises pembrolizumab. Pembrolizumab is a humanized monoclonal IgG4 (S228P) antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1). Pembrolizumab is described, for example, in U. S. Patent Nos. 8,354,509 and 8,900,587.
[0393] In some aspects, the anti-PD-1 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of pembrolizumab.
[0394] In some aspects, the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:79, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:80. In some aspects, the anti-PD-1 antibody comprises (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:81; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:82; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:83; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:84; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:85; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:86. In some aspects, the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:79 and 80, respectively. In some aspects, the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:77 and 78, respectively.
[0395] In some aspects, the anti-PD-1 antibody comprises cemiplimab (REGN2810). Cemiplimab is described, for example, in WO 2015 / 112800 and U. S. Patent No. 9,987,500.
[0396] In some aspects, the anti-PD-1 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of cemiplimab.
[0397] In some aspects, the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:35, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:36. In some aspects, the anti-PD-1 antibody comprises (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:37; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:38; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:39; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:40; (e) a light chain variable region CDR2 comprising the amino acid sequence AAS; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:42. In some aspects, the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:35 and 36, respectively. In some aspects, the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:33 and 34, respectively.
[0398] In some aspects, the anti-PD-1 antibody comprises spartalizumab (PDR001). Spartalizumab is described, for example, in WO 2015 / 112900 and U. S. Patent No. 9,683,048.
[0399] In some aspects, the anti-PD-1 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of spartalizumab.
[0400] In some aspects, the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:59, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:60. In some aspects, the anti-PD-1 antibody comprises (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:61; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:62; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:63; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:64; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:65; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:66. In some aspects, the anti-PD-1 antibodycomprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:59 and 60, respectively. In some aspects, the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:57 and 58, respectively.
[0401] In some aspects, the anti-PD-1 antibody comprises sasanlimab.
[0402] In some aspects, the anti-PD-1 antibody comprises the heavy and light chain variable region CDRs, the heavy and light chain variable regions, and / or the heavy and light chains of sasanlimab.
[0403] Anti-PD-1 antibodies usable in the disclosed methods also include isolated antibodies that bind specifically to human PD-1 and cross-compete for binding to human PD-1 with any anti-PD-1 antibody disclosed herein, e.g., nivolumab (see, e.g., U. S. Patent No. 8,008,449 and 8,779,105; WO 2013 / 173223). In some aspects, the anti-PD-1 antibody binds the same epitope as any of the anti-PD-1 antibodies described herein, e.g, nivolumab. The ability of antibodies to cross-compete for binding to an antigen indicates that these monoclonal antibodies bind to the same epitope region of the antigen and sterically hinder the binding of other cross-competing antibodies to that particular epitope region. These cross-competing antibodies are expected to have functional properties very similar those of the reference antibody, e.g, nivolumab, by virtue of their binding to the same epitope region of PD-1. Cross-competing antibodies can be readily identified based on their ability to cross-compete with nivolumab in standard PD-1 binding assays such as BIACORE analysis, ELISA assays or flow cytometry (see, e.g., WO 2013 / 173223).
[0404] In some aspects, the antibodies that cross-compete for binding to human PD- 1 with, or bind to the same epitope region as any human PD-1 antibody disclosed herein, e.g., nivolumab, are monoclonal antibodies. For administration to human subjects, these cross-competing antibodies are chimeric antibodies, engineered antibodies, or humanized or human antibodies. Such chimeric, engineered, humanized or human monoclonal antibodies can be prepared and isolated by methods well known in the art.
[0405] Anti-PD-1 antibodies usable in the methods of the disclosure also include antigen binding portions of the above full-length antibodies. It has been amply demonstrated that the antigen binding function of an antibody can be performed by fragments of a full-length antibody.
[0406] Anti-PD-1 antibodies suitable for use in the disclosed methods are antibodies that bind to PD-1 with high specificity and affinity, block the binding of PD-L1 and or PD-L2, and inhibit the immunosuppressive effect of the PD-1 signaling pathway. In any of the methods disclosed herein, an anti-PD-1 "antibody" includes an antigen binding portion or fragment thatbinds to the PD-1 receptor and exhibits the functional properties similar to those of whole antibodies in inhibiting ligand binding and up-regulating the immune system. In some aspects, the anti -PD-1 antibody or antigen binding portion thereof cross-competes with nivolumab for binding to human PD-1.
[0407] In some aspects, the anti-LAG-3 antibody comprises relatlimab, or an antigen binding portion thereof, and the anti -PD-1 antibody comprises nivolumab, or an antigen binding portion thereof.
[0408] In some aspects, the anti-LAG-3 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14.
[0409] In some aspects, the anti-LAG-3 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, respectively, and the anti-PD-1 antibody comprises a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively.
[0410] In some aspects, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively, and the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively.
[0411] In some aspects, the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 1 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively.
[0412] In some aspects, the anti-LAG-3 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs:21 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the amino acid sequences set forth in SEQ IDNOs:ll and 12, respectively.II. C. Endoglycosidase Hydrolase Enzyme
[0413] In some aspects, the endoglycosidase hydrolase enzyme in the methods disclosed herein cleaves hyaluronic acid at a hexosaminidic P (1-4) or (1-3) linkage.
[0414] In some aspects, the endoglycosidase hydrolase enzyme comprises a hyaluronidase.
[0415] In some aspects, the endoglycosidase hydrolase enzyme comprises a catalytic domain of hyaluronidase PH-20 (HuPH20), HYAL1, HYAL2, HYAL3, HYAL4, or HYALPS1.
[0416] In some aspects, the hyaluronidase comprises HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, or a variant or isoform thereof.
[0417] In some aspects, the endoglycosidase hydrolase enzyme comprises a recombinant human hyaluronidase enzyme, e.g., rHuPH20, or a fragment thereof.
[0418] In some aspects, the endoglycosidase hydrolase enzyme comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to amino acids 36-490 of SEQ ID NO: 87 as shown in Table 1. In some aspects, the endoglycosidase hydrolase enzyme comprises the catalytic domain of rHuPH20 (UniProt ID No. P38567-1). In some aspects, the endoglycosidase hydrolase enzyme comprises the rHuPH20 mature peptide (z.e., the endoglycosidase hydrolase enzyme comprises amino acids 36-490 of SEQ ID NO: 87).Table 1: Amino Acid Sequence of rHuPH20_ Signal peptide: underlined; mature protein: bold; propeptide: italics.
[0419] In some aspects, a single unit dose as disclosed herein comprises Halozyme Therapeutics’ ENHANZE drug-delivery technology (see U. S. Patent No. 7,767,429, which is incorporated by reference herein in its entirety). ENHANZE uses a co-formulation of an antibody with recombinant human hyaluronidase enzyme (rHuPH20), which removes traditional limitationson the volume of biologies and drugs that can be delivered subcutaneously due to the extracellular matrix (see U. S. Patent No. 7,767,429).
[0420] Recombinant human hyaluronidase PH20 (rHuPH20, Halozyme Therapeutics Inc.) is a glycosylated 447-amino acid single-chain recombinant human polypeptide that depolymerizes hyaluronan in the subcutaneous (SC) space locally at the site of injection. Hyaluronan is a repeating polymer of N-acetyl-glucosamine and glucuronic acid that contributes to the soluble gel-like component of the extracellular matrix of the skin. Depolymerization of hyaluronan by rHuPH20 results in a transient reduction in the viscosity of the gel-like phase of the extracellular matrix and increased hydraulic conductance that facilitates the dispersion and absorption of injected drugs (see rHuPH20 IB). Use of rHuPH20 enables the delivery of large volumes for rapid SC injections (for example, approximately 2 mL to 20 mL), which may shorten dose administration times, reduce administration frequency, and enable potential improvements to the PK profiles of coadministered drugs, including improved absorption, increased bioavailability, accelerated time to maximum concentration (Tmax), increased maximum concentration (Cmax), and decreased PK variability.
[0421] The half-life of rHuPH20 in skin is < 30 minutes, and the local permeability barrier in these tissues is restored to pre-injection levels within 24 hours to 48 hours after injection of hyaluronidase. A study showed that rHuPH20 was not detectable systemically in healthy volunteers and patients following SC administration at doses of 10,000 international units (IU) and 30,000 IU. Another study of the PK of rHuPH20 (Halozyme Study HALO-104-104) demonstrated that plasma concentrations of rHuPH20 rapidly declined, with a very short tl / 2 (< 10.4 min) and the plasma concentration became undetectable (<0.03 ng / mL) within 1.5 hours after the end of the IV infusion at for IV doses of 10,000 IU or 30,000 IU of rHuPH20.
[0422] Subcutaneous injection of rHuPH20 is generally well-tolerated in healthy participants, dehydrated pediatric participants, hospice and palliative care participants, participants with type 1 and 2 diabetes, and participants with rheumatoid arthritis. Subcutaneous injections of rHuPH20 either alone or coadministered with lactated Ringer’s, normal saline, co-injected drugs (morphine, ceftriaxone, insulin and insulin analogues) or biologic products (immunoglobulin G [IgG] and adalimumab) has been well-tolerated.
[0423] In some aspects, the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising one or more amino acid substitutions relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof.
[0424] In some aspects, the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising (i) one or more amino acid substitution in an alpha-helix region, (ii) one or more amino acid substitution in a linker region, (iii) deletion of one or more N-terminal and / or C-terminal amino acids, or (iv) any combination of (i)-(iii), relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof
[0425] In some aspects, the endoglycosidase hydrolase enzyme comprises a modified rHuPH20, wherein the modified rHuPH20 comprises: (a) one or more amino acid substitution in an alpha-helix region, a linker region, or both an alpha-helix region and a linker region relative to wild-type rHuPH20; (b) deletion of one or more N-terminal amino acid, one or more C-terminal amino acid, or one or more N-terminal amino acid and one or more C-terminal amino acid relative to wild-type rHuPH20; or (c) both (a) and (b).
[0426] Additional, non-limiting examples of endoglycosidase hydrolase enzymes are found in EP3636752, which is incorporated by reference herein in its entirety.
[0427] In some aspects, the endoglycosidase hydrolase enzyme is any polypeptide having endoglycosidase hydrolase enzyme activity disclosed in US Patent No. US 9,447,401; US 10,865,400; US 11,041,149; US 11,066,656; US 8,927,249; US 9,284,543; US 10,588,983; US 10 / 328,130; and / or US 9,993,529, each of which is incorporated by reference herein in its entirety. In some aspects, the endoglycosidase hydrolase enzyme is any polypeptide having endoglycosidase hydrolase enzyme activity disclosed in International Publication No. WO / 13 / 102144, WO / 10 / 077297, WO / 15 / 003167, WO / 04 / 078140 WO / 09 / 128917, WO / 12 / 174478, and / or WO / 12 / 174480, each of which is incorporated by reference herein in its entirety. In some aspects, the endoglycosidase hydrolase enzyme comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to an amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs: 88-136. In some aspects, the endoglycosidase hydrolase enzyme comprises an amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs: 88-136.
[0428] In some aspects, the endoglycosidase hydrolase enzyme is any polypeptide having endoglycosidase hydrolase enzyme activity disclosed in US Patent Application Publication No. US2021155913A1 and / or US2021363270A1; and / or International Publication Nos. WO / 20 / 022791, WO / 20 / 197230 and / or WO / 21 / 150079; each of which is incorporated by reference herein in its entirety. In some aspects, the endoglycosidase hydrolase enzyme comprisesan amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to an amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs: 137-347. In some aspects, the endoglycosidase hydrolase enzyme comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth in SEQ ID NO: 176. In some aspects, the endoglycosidase hydrolase enzyme comprises an amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs: 137-347. In some aspects, the endoglycosidase hydrolase enzyme comprises the amino acid sequence set forth in SEQ ID NO: 176. In some aspects, the endoglycosidase hydrolase enzyme is HP46 (SEQ ID NO: 348, corresponding to SEQ ID NO: 44 of Int'l Publication No. WO / 2020 / 197230).
[0429] It would be readily apparent to a person of ordinary skill in the art that the amount of the endoglycosidase hydrolase enzyme (e.g., rHuPH20) can be expressed in terms of international units (IU) or lU / mL or the amount of the endoglycosidase hydrolase enzyme (e.g., rHuPH20) can be expressed in terms mg / mL (or in other weight-based units). For example, in some aspects, the single unit dose comprises an amount of an endoglycosidase hydrolase enzyme (e.g., rHuPH20) expressed as at least about 500 HJ / mL or at least about 0.00455 mg / mL. In another example, in some aspects, the single unit dose comprises an amount of an endoglycosidase hydrolase enzyme (e.g., rHuPH20) expressed as at least about 2000 IU / mL or at least about 0.0182 mg / mL.ILD. Tumors
[0430] In some aspects, the tumor treated by a method as disclosed herein is recurrent or refractory.
[0431] In some aspects, the tumor is unresectable, advanced, and / or metastatic.
[0432] In some aspects, the tumor is a malignant tumor.
[0433] In some aspects, the method is a first line therapy.
[0434] In some aspects, the method is a second line therapy.
[0435] In some aspects, the method is a third line therapy.
[0436] In some aspects, the subject has progressed on or is intolerant of a prior therapy (e.g., a standard of care therapy). For example, the National Comprehensive Cancer Network(NCCN), an alliance of 21 major cancer centers in the USA, publishes the NCCN Clinical Practice Guidelines in Oncology (NCCN GUIDELINES®) that provide detailed up-to-date information on the standard of care treatments for a wide variety of cancers. See NCCN GUIDELINES®, 2024-2025, www.nccn.org / guidelines / category_l, last accessed January 2, 2025.
[0437] In some aspects, the subject is naive to prior systemic therapy.
[0438] In some aspects, the subject is naive to prior immuno-oncology therapy, the subject is naive to prior immuno-oncology for the tumor, or the tumor is naive to prior immuno-oncology therapy.
[0439] In some aspects, the tumor comprises a hepatocellular carcinoma, colorectal cancer, gastric cancer, small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), squamous NSCLC, nonsquamous NSCLC, solid cancer with liver metastatic disease, cervical cancer, breast cancer, triple-negative breast cancer, pancreatic cancer, urothelial cancer, prostate cancer, hormone refractory prostate adenocarcinoma, hematological cancer, squamous cell carcinoma, glioma, gastrointestinal cancer, renal cancer, clear cell carcinoma, ovarian cancer, liver cancer, endometrial cancer, kidney cancer, renal cell carcinoma (RCC), thyroid cancer, neuroblastoma, glioblastoma, glioblastoma multiforme, stomach cancer, bladder cancer, hepatoma, colon cancer, head and neck cancer, gastroesophageal cancer, germ cell tumor, pediatric sarcoma, sinonasal natural killer T-cell lymphoma, melanoma, bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, rectal cancer, solid tumor of childhood, cancer of the ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumor, brain cancer, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, environmentally-induced cancer, virus-related cancer or cancer of viral origin, or a combination thereof.
[0440] In some aspects, the tumor comprises a hepatocellular carcinoma, colorectal cancer, lung cancer, gastric cancer, renal cancer, prostate cancer, melanoma, hematological cancer, breast cancer, head and neck cancer, or a combination thereof.
[0441] In some aspects, the tumor comprises a breast cancer.
[0442] In some aspects, the tumor comprises a triple-negative breast cancer. As used herein, the term "triple-negative breast cancer" refers to a breast cancer that is characterized by alack of detectable expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 (HER2 or ErbB2).
[0443] In some aspects, the tumor comprises a head and neck cancer.II. D.l. Hepatocellular Carcinoma
[0444] In some aspects, the tumor comprises a hepatocellular carcinoma (HCC). The term " HCC" as used herein is interchangeable with any of the terms "liver cancer," "liver cell carcinoma," and "hepatoma."
[0445] In some aspects, the subject has progressed on or is intolerant to a prior therapy (e.g., a standard of care therapy, including a standard of care IL or 2L therapy). In some aspects, the prior therapy and / or standard of care therapy comprises a tyrosine kinase inhibitor, an antiangiogenesis agent, a checkpoint inhibitor, a checkpoint stimulator, a chemotherapeutic agent, an immunotherapeutic agent (e.g., an agent used in immuno-oncology therapy), a platinum agent, an alkylating agent, a taxane, a nucleoside analog, an antimetabolite, a topisomerase inhibitor, an anthracycline, a vinca alkaloid, or any combination thereof. In some aspects, the prior therapy comprises sorafenib (e.g., sorafenib tosylate, also known as NEXAVAR®, which is indicated for the treatment of patients with unresectable HCC), lenvatinib (e.g., lenvatinib mesylate, also known as LENVIMA®, which is indicated for IL treatment of patients with unresectable HCC), regorafenib (e.g., STIVARGA®, which is indicated for the treatment of patients with HCC who have been previously treated with sorafenib) and / or cabozantinib (e.g., cabozantinib S-malate, also known as CABOMETYX®, which is indicated for the treatment of patients with HCC who have been previously treated with sorafenib). In some aspects, the prior therapy comprises the combination of an anti-PD-Ll antibody (e.g., atezolizumab, also known as TECENTRIQ®) and an anti-VEGF antibody (e.g., bevacizumab, also known as AVASTIN®). The combination of atezolizumab and bevacizumab is indicated for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy. In some aspects, the prior therapy comprises an anti-VEGFR-2 antibody (e.g., ramucirumab, also known as CYRAMZA®, which is indicated as a single agent, for the treatment of patients with HCC who have an alpha fetoprotein of >400 ng / mL and have been treated with sorafenib). In some aspects, the prior therapy is an anti-PD-1 antibody (e.g., nivolumab, also known as OPDIVO®, or pembrolizumab, also known as KEYTRUDA®, each indicated as a single agent for the treatment of patients with HCC who have been previously treated with sorafenib). In some aspects, the prior therapy is the combination of an anti-PD-1 antibody (e.g., nivolumab / OPDIVO®) in combination with an anti-CTLA-4 antibody(e.g., ipilimumab, also known as YERVOY®). The combination of nivolumab and ipilimumab is indicated for the treatment of patients who have been previously treated with sorafenib.
[0446] In some aspects, the subject is naive to prior immuno-oncology (I-O) therapy. In some aspects, the subject has never received 1-0 therapy, has received 1-0 therapy for a cancer other than HCC, or has received 1-0 therapy for a previous HCC but not a current HCC. In some aspects, the subject is naive to prior 1-0 therapy, the subject is naive to prior 1-0 therapy for HCC, or the HCC is naive to prior 1-0 therapy. In some aspects, the prior 1-0 therapy is an antibody. In some aspects, the antibody binds to a checkpoint inhibitor. In some aspects, the prior 1-0 therapy is an anti-PD-1 antibody and / or the combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody.
[0447] In some aspects, the methods of the disclosure comprise administering to the subj ect an immunotherapy comprising the single unit dose based on the subject's performance status, liver function, and / or cancer stage. Performance status, liver function, and / or cancer stage can be indicated by any one or more systems in the art. In some aspects, the system is Child-Pugh score or status, Eastern Cooperative Oncology Group Performance Status (ECOG PS), and / or Barcelona Clinic Liver Cancer (BCLC) stage. In some aspects, the subject has a Child-Pugh score of 5-6, 7-9, or 10-15. In some aspects, the subject has a Child-Pugh status of A, B, or C. In some aspects, the subject has a Child-Pugh score of 5-6 and / or has Child-Pugh A status. In some aspects, the subject has a Child-Pugh score of 7-9 and / or has Child-Pugh B status. In some aspects, the subject has a Child-Pugh score of 10-15 and / or has Child-Pugh C status. In some aspects, the subject has an ECOG PS of 0, 1, 2, 3, or 4. In some aspects, the subject has a BCLC status of 0, A, B, C, or D. In some aspects, the subject has an ECOG PS of 0, a Child-Pugh score of 5-6, a Child-Pugh A (or Class A) status, and / or a BCLC stage of 0. In some aspects, the subject has an ECOG PS of 0, a Child-Pugh score of 5 or 6, a Child-Pugh A (or Class A) status, and / or a BCLC stage of A. In some aspects, the subject has an ECOG PS of 0, a Child-Pugh score of 7-9, a Child-Pugh B (or Class B) status, and / or a BCLC stage of B. In some aspects, the subject has an ECOG PS of 1 or 2, a Child-Pugh score of 5-6 or 7-9, a Child-Pugh A or B (Class A or Class B) status, and / or a BCLC stage of C. In some aspects, the subject has an ECOGPS of 3 or 4, a Child-Pugh score of 10-15, a Child-Pugh C (or Class C) status, and / or a BCLC stage of D.
[0448] In some aspects, the subj ect has microvascular invasion of HCC and / or extrahepatic spread of HCC. In some aspects, the subject lacks microvascular invasion of HCC and / or extrahepatic spread of HCC.
[0449] In some aspects, the HCC has an etiology associated with chronic liver disease, chronic liver inflammation, an infection, a toxin, aflatoxin Bl, alcoholic liver disease, tobacco use, metabolic syndrome, diabetes, obesity, and / or non-alcoholic fatty liver disease. In some aspects, the HCC is viral HCC ( / .<., the cause of HCC is a viral infection). In some aspects, the HCC is non-viral HCC ( / .<., the cause of HCC is any cause other than viral infection). In some aspects, the subject has an HBV infection. In some aspects, the subject has an HCV infection. In some aspects, the subject has an HBV infection and an HCV infection. In some aspects, the subject has an HIV infection and a HBV and / or HCV infection. In some aspects, the subject has alcoholic liver disease. In some aspects, the subject has metabolic syndrome, diabetes, and / or non-alcoholic fatty liver disease.ILD.2. Lung Cancer
[0450] In some aspects, the tumor comprises a lung cancer.
[0451] In some aspects, the lung cancer is recurrent following multi-modal therapy for locally advanced lung cancer.
[0452] In some aspects, the subject has not received a prior local or systemic anticancer therapy given as primary therapy for locally advanced disease.
[0453] In some aspects, the subject has not received a prior systemic therapy for cancer, the subject has not received a prior systemic therapy for lung cancer, or the subject has not received a prior systemic therapy for advanced or metastatic lung cancer.
[0454] In some aspects, the subject is naive to prior immuno-oncology (I-O) therapy. In some aspects, the subject has never received 1-0 therapy, has received 1-0 therapy for a cancer other than lung cancer, or has received 1-0 therapy for a previous lung cancer but not a current lung cancer. In some aspects, the subject is naive to prior 1-0 therapy, the subject is naive to prior 1-0 therapy for lung cancer, or the lung cancer is naive to prior 1-0 therapy. In some aspects, the prior 1-0 therapy is an antibody. In some aspects, the antibody binds to a checkpoint inhibitor. In some aspects, the prior 1-0 therapy is an anti-PD-1 antibody and / or the combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody.
[0455] In some aspects the subject has an ECOG PS of 0, 1, 2, 3, or 4. In some aspects, the subject has an ECOG PS of < 3. In some aspects, the subject has an ECOG PS of < 2. In some aspects, the subject has an ECOG PS of < 1.
[0456] In some aspects, lung cancer is staged based on a tumor (T) / node (N) / metastasis (M) staging system (T / N / M) such as the American Joint Committee on Cancer (AJCC)classification. See, e.g., https: / / www.cancer.org / cancer / lung-cancer / detection-diagnosis-staging / staging-nsclc.html, last accessed January 2, 2025.
[0457] Stages for lung cancer (e.g., NSCLC) include: occult (hidden) stage, Stage 0 (carcinoma in situ), Stage I (e.g., Stage IA1, Stage IA2, Stage IA3, and Stage IB NSCLC), Stage II (e.g., Stage IIA and Stage IIB NSCLC), Stage III (e.g., Stage IIIA, Stage IIIB, and Stage IIIC NSCLC), and Stage IV (e.g., Stage IVA and Stage IVB NSCLC).
[0458] In some aspects the subject is afflicted with an occult (hidden) stage lung cancer (e.g., NSCLC). In the occult stage, the cancer cannot be seen by imaging or bronchoscopy (TX), has not spread to lymph nodes (NO), and has not metastasized (MO) (TX / NO / MO).
[0459] In some aspects the subject is afflicted with a Stage 0 lung cancer (e.g., NSCLC). In Stage 0 (Tis / NO / MO), cancer cells are found only in the lining of the airways and have not invaded deeper into other lung tissues (Tis). NO and MO are as described above.
[0460] In some aspects, the subject is afflicted with a Stage I lung cancer (e.g., NSCLC). Stage I lung cancer is divided, e.g., into Stage IA1, Stage IA2, Stage IA3, and Stage IB for NSCLC. NO and MO are as described above. In Stage IA1 (Tlmi / NO / MO), the cancer is a minimally invasive adenocarcinoma, and the tumor is no larger than 3 centimeters (cm) across, with the part invading into deeper lung tissues not larger than 0.5 cm across (Tlmi). In Stage IA1 (Tla / NO / MO), the tumor is not larger than 1 cm across, has not grown into the membranes surrounding the lungs, and does not affect the main branches of the bronchi (Tla). In Stage IA2 (Tlb / NO / MO), the tumor is larger than 1 cm across but not larger than 2 cm across, has not grown into the membranes surrounding the lungs, and does not affect the main branches of the bronchi (Tib). In Stage IA3 (Tlc / NO / MO), the tumor is larger than 2 cm across but not larger than 3 cm across, has not grown into the membranes surrounding the lungs, and does not affect the main branches of the bronchi (Tic). In Stage IB (T2a / N0 / M0), one or more of the following is true: 1) the tumor is larger than 3 cm across but not larger than 4 cm across; 2) the cancer has spread to the main bronchus and is at least 2 cm below where the trachea joins the bronchus; 3) the cancer has spread to the innermost layer of the membrane that covers the lung and is not larger than 4 cm across; or 4) the tumor is not larger than 4 cm across but is partially clogging the airways (T2a).
[0461] In some aspects, the subject is afflicted with a Stage II lung cancer (e.g., NSCLC). Stage II is divided, e.g., into Stage IIA (T2b / N0 / M0) and IIB (Tla / Tlb / Tlc / Nl / MO or T2a / T2b / Nl / M0 or T3 / N0 / M0) for NSCLC. NO and MO are as described above. In Stage IIA, one or more of the following is true: 1) the tumor is larger than 4 cm across but not larger than 5 cm across; 2) the cancer has spread to the main bronchus, is at least 2 centimeters below where thetrachea joins the bronchus, and the tumor is larger than 4 cm across but not larger than 5 cm across; 3) the cancer has spread to the innermost layer of the membrane that covers the lung, and the tumor is larger than 4 cm across but not larger than 5 cm across; or 4) the tumor is larger than 4 cm across but not larger than 5 cm across and is partially clogging the airways (T2b). In stage IIB, the cancer has either spread to the lymph nodes or not. If the cancer has spread to the lymph nodes, then the cancer can only have spread to the lymph nodes on the same side of the chest as the tumor, and the lymph nodes with cancer are within the lung or near the bronchus (Nl). For Tla / Tlb / Tlc / Nl / MO, the tumor is no larger than 3 cm across, has not grown into the membranes surrounding the lungs, and does not affect the main branches of the bronchi (Tla / Tlb / Tlc). For T2a / T2b / Nl / M0, one or more of the following is true: 1) the tumor is larger than 3 cm across but not larger than 5 cm across; 2) the cancer has spread to the main bronchus, is at least 2 centimeters below where the trachea joins the bronchus, and the tumor is not larger than 5 cm across; 3) the cancer has spread to the innermost layer of the membrane that covers the lung and is not larger than 5 cm across; or 4) the tumor is not larger than 5 cm across and is partially clogging the airways (T2a / T2b). In T3 / N0 / M0, the cancer has not spread to the lymph nodes or metastasized but one or more of the following is true: 1) the cancer is larger than 5 cm across but not larger than 7 cm across; 2) the cancer has grown into the chest wall, the parietal pleura, the phrenic nerve, or the parietal pericardium; or 3) the same lobe of a lung has 2 or more separate tumor nodules (T3).
[0462] In some aspects, the subject is afflicted with a Stage III lung cancer (e.g., NSCLC). Stage III is divided, e.g., into Stage IIIA (Tla / Tlb / Tlc / N2 / M0 or T2a / T2b / N2 / M0 or T3 / N1 / M0 or T4 / N0 or N1 / M0), IIIB (Tla / Tlb / Tlc / N3 / M0 or T2a / T2b / N3 / M0 or T3 / N2 / M0 or T4 / N2 / M0), and IIIC (T3 / N3 / M0 or T4 / N3 / M0) for NSCLC. Tla / Tlb / Tlc, T2a / T2b, T3, NO, Nl, and MO are as described above. For N2, the cancer has spread to lymph nodes around the carina or in the mediastinum on the same side as the tumor. For N3, the cancer has spread to lymph nodes on either side of the body near the collarbone, and / or has spread on the other side of the body from the main tumor to hilar or mediastinal lymph nodes. For T4, one or more of the following is true: 1) the tumor is larger than 7 cm across; 2) the tumor has grown into the mediastinum, the heart, the large blood vessels near the heart (e.g., the aorta), the trachea, the esophagus, the diaphragm, the backbone, or the carina; or 3) 2 or more tumor nodules are present in different lobes of the same lung.
[0463] In some aspects, the subject is afflicted with a Stage IV lung cancer (e.g., NSCLC). Stage IV is divided, e.g., into Stage IVA (Any T / Any N / Mla or Any T / Any N / Mlb) and IVB (Any T / Any N / Mlc) for NSCLC. For Any T, the tumor can be of any size and can have grown intonearby structures or not have grown into them. For Any N, the cancer can have reached nearby lymph nodes or not have reached them. For Mia, one or more of the following is true: 1) the cancer has spread to both lungs; 2) cancer cells are found in the fluid around the lung; 3) cancer cells are found in the fluid around the heart. For Mlb, the cancer has spread as a single tumor to a distant lymph node or another organ (e.g., the liver, bones, or brain). For Mlc, the cancer has spread as two or more tumors to distant lymph nodes and / or another organ (e.g., the liver, bones, or brain).
[0464] In some aspects, the lung cancer is small cell lung cancer (SCLC). In some aspects, staging of the SCLC is by T / N / M staging. In some aspects, rather than T / N / M staging, the SCLC is staged as either limited stage or extensive stage. Limited stage SCLC is confined to one lung and / or the local lymph nodes. Extensive stage SCLC is found in both lungs and / or distant sites in the body.
[0465] In some aspects, the lung cancer is non-small cell lung cancer (NSCLC). NSCLC includes NSCLC with a histology that is “not otherwise specified” (NOS), NSCLC with a squamous histology (SQ), and NSCLC with a non-squamous histology (NSQ, including adenocarcinoma, large cell, and undifferentiated carcinoma). In some aspects, the NSCLC has a squamous histology. In some aspects, the NSCLC has a non-squamous histology. In some aspects, staging of the NSCLC is by T / N / M staging. In some aspects, the NSCLC comprises locally advanced Stage IIIA, IIIB, or IIIC NSCLC.
[0466] Surgery (z.e., surgical resection), radiotherapy (RT, also interchangeably referred to herein as radiation therapy), and chemotherapy are three modalities commonly used to treat NSCLC patients. As a class, NSCLCs are relatively insensitive to chemotherapy and RT, compared to small cell carcinoma. In general, for patients with Stage I or II disease, surgical resection has provided the best chance for cure, with chemotherapy often used both pre-operatively and post-operatively. RT can also be used as adjuvant therapy for patients with resectable NSCLC, the primary local treatment, or as palliative therapy for patients with incurable NSCLC. Patients with advanced or metastatic disease (e.g., Stage IV NSCLC) who have a good performance status (PS) can benefit from chemotherapy.
[0467] Specific targeted therapies have also been developed for the treatment of advanced or metastatic NSCLC in subjects with sensitizing mutations in genes for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS-1, neurotrophin receptor tyrosine kinase (NTRK), and B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF, e.g., the BRAF V600E mutation).
[0468] In some aspects, the subject has an EGFR, ALK, NTRK, ROS-1, or BRAF mutation sensitive to targeted inhibitor therapy.
[0469] In some aspects, the subj ect has no EGFR, ALK, NTRK, ROS- 1, or BRAF mutation sensitive to targeted inhibitor therapy.II. D.3. Colorectal Carcinoma
[0470] In some aspects, the tumor comprises a colorectal carcinoma (CRC).
[0471] In some aspects, the CRC is a colon cancer, a rectal cancer, or a combination thereof.
[0472] Colon cancer presents in five stages: Stage 0 (Carcinoma in Situ), Stage I, Stage II, Stage III and Stage IV. Standard of care treatments for colon cancer include: 1) surgery, including a local excision, resection of the colon with anastomosis, or resection of the colon with colostomy; 2) radiofrequency ablation; 3) cryosurgery; 4) chemotherapy; 5) radiation therapy; and 6) targeted therapies, including monoclonal antibodies and angiogenesis inhibitors. In some aspects, a method of the disclosure further comprises administering a standard of care therapy for the treatment of colon cancer.
[0473] Rectal cancer presents in five stages: Stage 0 (Carcinoma in Situ), Stage I, Stage II, Stage III and Stage IV. Standard of care treatments for rectal cancer include: 1) Surgery, including polypectomy, local excision, resection, radiofrequency ablation, cryosurgery, and pelvic exenteration; 2) radiation therapy; 3) chemotherapy; and 4) targeted therapy, including monoclonal antibody therapy. In some aspects, a method of the disclosure further comprises administering a standard of care therapy for the treatment of rectal cancer.
[0474] In some aspects, the subject has progressed on or is intolerant to a prior therapy (e.g., a standard of care therapy, including a standard of care IL or 2L therapy).
[0475] In some aspects, the prior therapy comprises a fluoropyrimidine, oxaliplatin, irinotecan, anti-vascular endothelial growth factor (VEGF) therapy, anti-epidermal growth factor receptor (EGFR) therapy (e.g., cetuximab or panitumumab) for CRC comprising a Kristen Rat Sarcoma Viral Oncogene Homologue (KRAS) mutation, regorafenib, TAS- 102, or any combination thereof.
[0476] In some aspects, the subject has received one, two, three, four, or more prior therapies.
[0477] In some aspects, the subject is naive to prior systemic therapy for advanced and / or metastatic CRC.
[0478] In some aspects, the subject is naive to prior immuno-oncology (I-O) therapy. In some aspects, the subject has never received 1-0 therapy, has received 1-0 therapy for a cancer other than CRC, or has received 1-0 therapy for a previous CRC but not a current CRC. In some aspects, the subject is naive to prior 1-0 therapy, the subject is naive to prior 1-0 therapy for CRC, or the CRC is naive to prior 1-0 therapy. In some aspects, the prior 1-0 therapy is an antibody. In some aspects, the antibody binds to a checkpoint inhibitor. In some aspects, the prior 1-0 therapy is an anti-PD-1 antibody and / or the combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody.
[0479] In some aspects, the CRC comprises adenocarcinoma histology.
[0480] Approximately 4% of CRCs are associated with high microsatellite instability (MSI-H), which is a condition of genetic hypermutability that results from deficient DNA mismatch repair (dMMR). The presence of MSI-H represents phenotypic evidence of dMMR. In most cases, the genetic basis for MSI-H CRC is an inherited germline alteration in any one or more of the five human MMR genes: MLH1, MSH2, MSH6, PMS1, or PMS2.
[0481] In contrast to MSI-H, microsatellite stability (MSS) is the molecular fingerprint of a proficient mismatch repair (pMMR) system. The term MSS is widely accepted as a surrogate terminology for pMMR tumors. Approximately 85% CRCs display MSS without novel microsatellite alleles.
[0482] In colorectal cancer, MSI-H is associated with increases in immune infiltration and expression of immune checkpoint regulators, while MSS is typically associated with an immunosuppressive tumor microenvironment that blunts activation of anti-tumor immune responses. But, a subset of MSS CRC patients displays a MSI-like tumor immune contexture, characterized by high T cell activation and LAG-3 upregulation.
[0483] Patients with MSI-H mCRC are less likely to benefit from conventional chemotherapy than patients with MSS mCRC. But, studies have confirmed that MSS identification can be prognostic in that MSS CRC has a worse prognosis than MSI-H CRC.
[0484] There are several well-established methods to differentiate MSS from MSI-H. One is immunohistochemistry (IHC) for MMR. IHC MMR testing consists of staining of tumor tissue for loss of expression of f...
Claims
WHAT IS CLAIMED IS:
1. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg or about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg to about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
2. The method of claim 1, wherein the anti-PD-1 antibody is administered to the subject at a dose of about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 800 mg, about 880 mg, about 960 mg, about 1020 mg, about 1080 mg, about 1140 mg, or about 1200 mg.
3. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
4. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
5. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 800 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
6. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
7. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
8. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
9. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
10. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
11. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
12. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 800 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
13. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
14. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
15. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
16. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
17. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
18. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
19. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 800 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
20. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
21. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
22. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
23. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU to about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
24. The method of any one of claims 1 to 23, wherein the single unit dose has a volume of about 9 mL to about 16 mL.
25. The method of any one of claims 1 to 24, wherein the single unit dose is administered once about every two, three, or four weeks.
26. The method of any one of claims 1 to 25, wherein the endoglycosidase hydrolase enzyme is administered at a dose of about 18,000 IU, about 19,000 IU, about 20,000 IU, about 21,000 IU, about 22,000 IU, about 23,000 IU, about 24,000 IU, about 25,000 IU, about 26,000 IU, about 27,000 IU, about 28,000 IU, about 29,000 IU, about 30,000 IU, about 31,000 IU, or about 32,000 IU.
27. The method of claim 26, wherein the endoglycosidase hydrolase enzyme is administered at a dose of about 32,000 IU.
28. The method of claim 26, wherein the endoglycosidase hydrolase enzyme is administered at a dose of about 30,000 IU.
29. The method of claim 26, wherein the endoglycosidase hydrolase enzyme is administered at a dose of about 26,000 IU.
30. The method of claim 26, wherein the endoglycosidase hydrolase enzyme is administered at a dose of about 24,000 IU.
31. The method of claim 26, wherein the endoglycosidase hydrolase enzyme is administered at a dose of about 22,000 IU.
32. The method of claim 26, wherein the endoglycosidase hydrolase enzyme is administered at a dose of about 20,000 IU.
33. The method of claim 26, wherein the endoglycosidase hydrolase enzyme is administered at a dose of about 19,000 IU.
34. The method of claim 26, wherein the endoglycosidase hydrolase enzyme is administered at a dose of about 18,000 IU.
35. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
36. The method of claim 35, wherein the single unit dose has a volume of about 16 mL.
37. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 16,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
38. The method of claim 37, wherein the single unit dose has a volume of about 8 mL.
39. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
40. The method of claim 39, wherein the single unit dose has a volume of about 12 mL.
41. The method of any one of claims 35 to 40, wherein the single unit dose comprises a total antibody concentration of about 120 mg / mL.
42. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 30,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
43. The method of claim 42, wherein the single unit dose has a volume of about 15 mL.
44. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 15,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and theendoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
45. The method of claim 44, wherein the single unit dose has a volume of about 7.5 mL.
46. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 22,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
47. The method of claim 46, wherein the single unit dose has a volume of about 11.25 mL.
48. The method of any one of claims 42 to 47, wherein the single unit dose comprises a total antibody concentration of about 128 mg / mL.
49. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 25,600 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
50. The method of claim 49, wherein the single unit dose has a volume of about 12.8 mL.
51. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of 12,800 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
52. The method of claim 51, wherein the single unit dose has a volume of about 6.4 mL.
53. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 19,200 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
54. The method of claim 53, wherein the single unit dose has a volume of about 9.6 mL.
55. The method of any one of claims 49 to 54, wherein the single unit dose comprises a total antibody concentration of about 150 mg / mL.
56. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
57. The method of claim 56, wherein the single unit dose has a volume of about 12 mL.
58. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of 12,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
59. The method of claim 58, wherein the single unit dose has a volume of about 6 mL.
60. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
61. The method of claim 60, wherein the single unit dose has a volume of about 9 mL.
62. The method of any one of claims 56 to 61, wherein the single unit dose comprises a total antibody concentration of about 160 mg / mL.
63. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 32,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
64. The method of claim 63, wherein the single unit dose has a volume of about 16 mL.
65. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 16,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
66. The method of claim 65, wherein the single unit dose has a volume of about 8 mL.
67. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
68. The method of claim 67, wherein the single unit dose has a volume of about 12 mL.
69. The method of any one of claims 63 to 68, wherein the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
70. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose ofabout 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
71. The method of claim 70, wherein the single unit dose has a volume of about 9 mL.
72. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 9,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
73. The method of claim 72, wherein the single unit dose has a volume of about 4.5 mL.
74. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 13,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
75. The method of claim 74, wherein the single unit dose has a volume of about 6.75 mL.
76. The method of any one of claims 70 to 75, wherein the antibodies in the single unit dose are at a concentration of about 160 mg / mL.
77. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 19,200 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
78. The method of claim 77, wherein the single unit dose has a volume of about 9.6 mL.
79. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 9,600 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
80. The method of claim 79, wherein the single unit dose has a volume of about 4.8 mL.
81. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 14,400 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
82. The method of claim 81, wherein the single unit dose has a volume of about 7.2 mL.
83. The method of any one of claims 77 to 82, wherein the single unit dose comprises a total antibody concentration of about 150 mg / mL.
84. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 20,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
85. The method of claim 84, wherein the single unit dose has a volume of about 10 mL.
86. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 10,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
87. The method of claim 86, wherein the single unit dose has a volume of about 5 mL.
88. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 15,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
89. The method of claim 88, wherein the single unit dose has a volume of about 7.5 mL.
90. The method of any one of claims 84 to 89, wherein the single unit dose comprises a total antibody concentration of about 144 mg / mL.
91. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
92. The method of claim 91, wherein the single unit dose has a volume of about 12 mL.
93. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 12,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
94. The method of claim 93, wherein the single unit dose has a volume of about 6 mL.
95. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and theendoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
96. The method of claim 95, wherein the single unit dose has a volume of about 9 mL.
97. The method of any one of claims 91 to 96, wherein the antibodies in the single unit dose are at a concentration of about 120 mg / mL.
98. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 16,800 IU, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
99. The method of claim 98, wherein the single unit dose has a volume of about 8.4 mL.
100. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 8,400 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
101. The method of claim 100, wherein the single unit dose has a volume of about 4.2 mL.
102. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 12,600 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
103. The method of claim 102, wherein the single unit dose has a volume of about 6.3 mL.
104. The method of any one of claims 98 to 103, wherein the single unit dose comprises a total antibody concentration of about 150 mg / mL.
105. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
106. The method of claim 105, wherein the single unit dose has a volume of about 9 mL.
107. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 9,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
108. The method of claim 107, wherein the single unit dose has a volume of about 4.5 mL.
109. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 13,500 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
110. The method of claim 109, wherein the single unit dose has a volume of about 6.75 mL.
111. The method of any one of claims 105 to 110, wherein the single unit dose comprises a total antibody concentration of about 140 mg / mL.
112. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 20,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
113. The method of claim 112, wherein the single unit dose has a volume of about 10 mL.
114. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 10,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
115. The method of claim 114, wherein the single unit dose has a volume of about 5 mL.
116. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 15,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
117. The method of claim 116, wherein the single unit dose has a volume of about 7.5 mL.
118. The method of any one of claims 112 to 117, wherein the single unit dose comprises a total antibody concentration of about 126 mg / mL.
119. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme hyaluronidase at a dose of about 24,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
120. The method of claim 119, wherein the single unit dose has a volume of about 12 mL.
121. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 270 mg, and (iii) an endoglycosidase hydrolase enzyme hyaluronidase at a dose of about 12,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and theendoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
122. The method of claim 121, wherein the single unit dose has a volume of about 6 mL.
123. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 405 mg, and (iii) an endoglycosidase hydrolase enzyme hyaluronidase at a dose of about 18,000 IU, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
124. The method of claim 123, wherein the single unit dose has a volume of about 9 mL.
125. The method of any one of claims 119 to 124, wherein the single unit dose comprises a total antibody concentration of about 105 mg / mL.
126. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg to about 1200 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg to about 1200 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
127. The method of claim 126, wherein the single unit dose is administered to the subject once about every two, three, or four weeks.
128. The method of claim 126 or 127, wherein the anti-LAG-3 antibody is administered at a dose of about 540 mg to about 1200 mg, about 600 mg to about 1200 mg, about 660 mg to about 1200 mg, about 720 mg to about 1200 mg, about 780 mg to about 1200 mg, about 840 mg to about 1200 mg, about 900 mg to about 1200 mg, about 960 mg to about 1200 mg, about 1020 mg to about 1200 mg, about 1080 mg to about 1200 mg, about 1140 mg to about 1200 mg, about 480 mg to about 1140 mg, about 540 mg to about 1140 mg, about 600 mg to about 1140 mg, about 660 mg to about 1140 mg, about 720 mg to about 1140 mg, about 780 mg to about 1140 mg, about 840 mg to about 1140 mg, about 900 mg to about 1140 mg, about 960 mg to about 1140 mg, about 1020 mg to about 1140 mg, about 1080 mg to about 1140 mg, about 480 mg to about 1080 mg, about540 mg to about 1080 mg, about 600 mg to about 1080 mg, about 660 mg to about 1080 mg, about 720 mg to about 1080 mg, about 780 mg to about 1080 mg, about 840 mg to about 1080 mg, about 900 mg to about 1080 mg, about 960 mg to about 1080 mg, about 1020 mg to about 1080 mg, about 480 mg to about 1020 mg, about 540 mg to about 1020 mg, about 600 mg to about 1020 mg, about 660 mg to about 1020 mg, about 720 mg to about 1020 mg, about 780 mg to about 1020 mg, about 840 mg to about 1020 mg, about 900 mg to about 1020 mg, about 960 mg to about 1020 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 900 mg to about 960 mg, about 480 mg to about 900 mg, about 540 mg to about 900 mg, about 600 mg to about 900 mg, about 660 mg to about 900 mg, about 720 mg to about 900 mg, about 780 mg to about 900 mg, about 840 mg to about 900 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, or about 480 mg to about 540 mg.
129. The method of any one of claims 126 to 128, wherein the anti-LAG-3 antibody is administered at a dose of about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, about 960 mg, about 1020 mg, about 1080 mg, about 1140 mg, or about 1200 mg.
130. The method of any one of claims 126 to 129, wherein the anti-PD-1 antibody is administered at a dose of about 540 mg to about 1200 mg, about 600 mg to about 1200 mg, about 660 mg to about 1200 mg, about 720 mg to about 1200 mg, about 780 mg to about 1200 mg, about 840 mg to about 1200 mg, about 900 mg to about 1200 mg, about 960 mg to about 1200 mg, about 1020 mg to about 1200 mg, about 1080 mg to about 1200 mg, about 1140 mg to about 1200 mg, about 480 mg to about 1140 mg, about 540 mg to about 1140 mg, about 600 mg to about 1140 mg, about 660 mg to about 1140 mg, about 720 mg to about 1140 mg, about 780 mg to about 1140 mg, about 840 mg to about 1140 mg, about 900 mg to about 1140 mg, about 960 mg to about 1140 mg, about 1020 mg to about 1140 mg, about 1080 mg to about 1140 mg, about 480 mg to about 1080 mg, about 540 mg to about 1080 mg, about 600 mg to about 1080 mg, about 660 mg to about 1080mg, about 720 mg to about 1080 mg, about 780 mg to about 1080 mg, about 840 mg to about 1080 mg, about 900 mg to about 1080 mg, about 960 mg to about 1080 mg, about 1020 mg to about 1080 mg, about 480 mg to about 1020 mg, about 540 mg to about 1020 mg, about 600 mg to about 1020 mg, about 660 mg to about 1020 mg, about 720 mg to about 1020 mg, about 780 mg to about 1020 mg, about 840 mg to about 1020 mg, about 900 mg to about 1020 mg, about 960 mg to about 1020 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 900 mg to about 960 mg, about 480 mg to about 900 mg, about 540 mg to about 900 mg, about 600 mg to about 900 mg, about 660 mg to about 900 mg, about 720 mg to about 900 mg, about 780 mg to about 900 mg, about 840 mg to about 900 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, or about 480 mg to about 540 mg.
131. The method of any one of claims 126 to 130, wherein the anti-PD-1 antibody is administered at a dose of about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, about 960 mg, about 1020 mg, about 1080 mg, about 1140 mg, or about 1200 mg.
132. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 240 mg to about 600 mg, (ii) an anti-PD-1 antibody at a dose of about 240 mg to about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
133. The method of claim 132, wherein the single unit dose is administered to the subject once about every two weeks.
134. The method of claim 132 or 133, wherein the anti-LAG-3 antibody is administered at a dose of about 300 mg to about 600 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 240 mg to about 540 mg, about 300 mg to about 540 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 240 mg to about 480 mg, about 300 mg to about 480 mg, about 360 mg to about 480 mg, about 420 mg to about 480 mg, about 240 mg to about 420 mg, about 300 mg to about 420 mg, about 360 mg to about 420 mg, about 240 mg to about 360 mg, about 300 mg to about 360 mg, or about 240 mg to about 300 mg.
135. The method of any one of claims 132 to 134, wherein the anti-LAG-3 antibody is administered at a dose of about 240 mg, about 300 mg, about 360 mg, about 420 mg, about 480 mg, about 540 mg, or about 600 mg.
136. The method of any one of claims 132 to 135, wherein the anti-PD-1 antibody is administered at a dose of about 300 mg to about 600 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 240 mg to about 540 mg, about 300 mg to about 540 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 240 mg to about 480 mg, about 300 mg to about 480 mg, about 360 mg to about 480 mg, about 420 mg to about 480 mg, about 240 mg to about 420 mg, about 300 mg to about 420 mg, about 360 mg to about 420 mg, about 240 mg to about 360 mg, about 300 mg to about 360 mg, or about 240 mg to about 300 mg.
137. The method of any one of claims 132 to 136, wherein the anti-PD-1 antibody is administered at a dose of about 240 mg, about 300 mg, about 360 mg, about 420 mg, about 480 mg, about 540 mg, or about 600 mg.
138. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg to about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg to about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose.
139. The method of claim 138, wherein the single unit dose is administered to the subject once about every three or four weeks.
140. The method of claim 138 or 139, wherein the anti-LAG-3 antibody is administered at a dose of about 420 mg to about 960 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 360 mg to about 840 mg, about 420 mg to about 840 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 360 mg to about 780 mg, about 420 mg to about 780 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 360 mg to about 720 mg, about 420 mg to about 720 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 360 mg to about 660 mg, about 420 mg to about 660 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 360 mg to about 600 mg, about 420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 360 mg to about 480 mg, about 420 mg to about 480 i ng, or about 360 mg to about 42( ) mg.
141. The method of any one of claims 138 to 140, wherein the anti-LAG-3 antibody is administered at a dose of about 360 mg, about 420 mg, about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, or about 960 mg.
142. The method of any one of claims 138 to 141, wherein the anti-PD-1 antibody is administered at a dose of about 420 mg to about 960 mg, about 480 mg to about 960 mg, about 540 mg to about 960 mg, about 600 mg to about 960 mg, about 660 mg to about 960 mg, about 720 mg to about 960 mg, about 780 mg to about 960 mg, about 840 mg to about 960 mg, about 360 mg to about 840 mg, about 420 mg to about 840 mg, about 480 mg to about 840 mg, about 540 mg to about 840 mg, about 600 mg to about 840 mg, about 660 mg to about 840 mg, about 720 mg to about 840 mg, about 780 mg to about 840 mg, about 360 mg to about 780 mg, about 420 mg to about 780 mg, about 480 mg to about 780 mg, about 540 mg to about 780 mg, about 600 mg to about 780 mg, about 660 mg to about 780 mg, about 720 mg to about 780 mg, about 360 mg to about 720 mg, about 420 mg to about 720 mg, about 480 mg to about 720 mg, about 540 mg to about 720 mg, about 600 mg to about 720 mg, about 660 mg to about 720 mg, about 360 mg to about 660 mg, about 420 mg to about 660 mg, about 480 mg to about 660 mg, about 540 mg to about 660 mg, about 600 mg to about 660 mg, about 360 mg to about 600 mg, about420 mg to about 600 mg, about 480 mg to about 600 mg, about 540 mg to about 600 mg, about 360 mg to about 540 mg, about 420 mg to about 540 mg, about 480 mg to about 540 mg, about 360 mg to about 480 mg, about 420 mg to about 480 mg, or about 360 mg to about 420 mg.
143. The method of any one of claims 138 to 142, wherein the anti-PD-1 antibody is administered at a dose of about 360 mg, about 420 mg, about 480 mg, about 540 mg, about 600 mg, about 660 mg, about 720 mg, about 780 mg, about 840 mg, about 900 mg, or about 960 mg.
144. The method of any one of claims 138 to 143, wherein the anti-LAG-3 antibody is administered at a dose of about 420 mg and the anti-PD-1 antibody is administered at a dose of about 420 mg.
145. The method of any one of claims 126 to 143, wherein the anti-LAG-3 antibody is administered at a dose of about 480 mg and the anti-PD-1 antibody is administered at a dose of about 480 mg.
146. The method of any one of claims 126 to 143, wherein the anti-LAG-3 antibody is administered at a dose of about 540 mg and the anti-PD-1 antibody is administered at a dose of about 540 mg.
147. The method of any one of claims 126 to 143, wherein the anti-LAG-3 antibody is administered at a dose of about 600 mg and the anti-PD-1 antibody is administered at a dose of about 600 mg.
148. The method of any one of claims 126 to 131 or 138 to 143, wherein the anti-LAG-3 antibody is administered at a dose of about 660 mg and the anti-PD-1 antibody is administered at a dose of about 660 mg.
149. The method of any one of claims 126 to 131 or 138 to 143, wherein the anti-LAG-3 antibody is administered at a dose of about 720 mg and the anti-PD-1 antibody is administered at a dose of about 720 mg.
150. The method of any one of claims 126 to 131 or 138 to 143, wherein the anti-LAG-3 antibody is administered at a dose of about 780 mg and the anti-PD-1 antibody is administered at a dose of about 780 mg.
151. The method of any one of claims 126 to 131 or 138 to 143, wherein the anti -LAG-3 antibody is administered at a dose of about 840 mg and the anti-PD-1 antibody is administered at a dose of about 840 mg.
152. The method of any one of claims 126 to 131 or 138 to 143, wherein the anti-LAG-3 antibody is administered at a dose of about 900 mg and the anti-PD-1 antibody is administered at a dose of about 900 mg.
153. The method of any one of claims 126 to 131 or 138 to 143, wherein the anti-LAG-3 antibody is administered at a dose of about 960 mg and the anti-PD-1 antibody is administered at a dose of about 960 mg.
154. The method of any one of claims 126 to 131, wherein the anti-LAG-3 antibody is administered at a dose of about 1020 mg and the anti-PD-1 antibody is administered at a dose of about 1020 mg.
155. The method of any one of claims 126 to 131, wherein the anti-LAG-3 antibody is administered at a dose of about 1080 mg and the anti-PD-1 antibody is administered at a dose of about 1080 mg.
156. The method of any one of claims 126 to 131, wherein the anti-LAG-3 antibody is administered at a dose of about 1140 mg and the anti-PD-1 antibody is administered at a dose of about 1140 mg.
157. The method of any one of claims 126 to 131, wherein the anti-LAG-3 antibody is administered at a dose of about 1200 mg and the anti-PD-1 antibody is administered at a dose of about 1200 mg.
158. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 480 mg, (ii) an anti-PD-1 antibody at a dose of about 480 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
159. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 600 mg, (ii) an anti-PD-1 antibody at a dose of about 600 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
160. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 360 mg, (ii) an anti-PD-1 antibody at a dose of about 360 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every two weeks.
161. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 720 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
162. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 900 mg, (ii) an anti-PD-1 antibody at a dose of about 900 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
163. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti-LAG-3 antibody at a dose of about 960 mg, (ii) an anti-PD-1 antibody at a dose of about 960 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti-LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every four weeks.
164. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 720 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
165. A method of treating a tumor in a subject in need thereof comprising subcutaneously administering to the subject (i) an anti -LAG-3 antibody at a dose of about 540 mg, (ii) an anti-PD-1 antibody at a dose of about 540 mg, and (iii) an endoglycosidase hydrolase enzyme at a dose of about 2000 IU / mL, wherein the anti -LAG-3 antibody, the anti-PD-1 antibody, and the endoglycosidase hydrolase enzyme are formulated in a single unit dose that is administered to the subject once about every three weeks.
166. The method of any one of claims 126 to 165, wherein the single unit dose comprises a total antibody concentration of about 100 mg / mL or more.
167. The method of any one of claims 166, wherein the single unit dose comprises a total antibody concentration of about 100 mg / mL to about 500 mg / mL, about 100 mg / mL to about 450 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 350 mg / mL, about 100 mg / mL to about 300 mg / mL, about 100 mg / mL to about 250 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 150 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 130 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 115 mg / mL, about 100 mg / mL to about 110 mg / mL, about 100 mg / mL to about 105 mg / mL, about 110 mg / mL to about 500 mg / mL, about 110 mg / mL to about 450 mg / mL, about 110 mg / mL to about 400 mg / mL, about 110 mg / mL to about 350 mg / mL, about 110 mg / mL to about 300 mg / mL, about 110 mg / mL to about 250 mg / mL, about 110 mg / mL to about 200 mg / mL, about 110 mg / mL to about 150 mg / mL, about 110 mg / mL to about 140 mg / mL, about 110 mg / mL to about 130 mg / mL, about 110 mg / mL to about 120 mg / mL, about 110 mg / mL to about 115 mg / mL, about 115 mg / mL to about 500 mg / mL, about 115 mg / mL to about 450 mg / mL, about 115 mg / mL to about 400 mg / mL, about 115 mg / mL to about 350 mg / mL, about 115 mg / mL to about 300 mg / mL, about 115 mg / mL to about 250 mg / mL, about 115 mg / mL to about 200 mg / mL, about 115 mg / mL to about 150 mg / mL, about 115 mg / mL to about 140 mg / mL, about 115 mg / mL to about 130 mg / mL, about 115 mg / mL to about 120 mg / mL, about 120 mg / mL to about 450 mg / mL, about 120mg / mL to about 400 mg / mL, about 120 mg / mL to about 350 mg / mL, about 120 mg / mL to about 300 mg / mL, about 120 mg / mL to about 250 mg / mL, about 120 mg / mL to about 200 mg / mL, about 120 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 130 mg / mL, about 150 mg / mL to about 500 mg / mL, about 150 mg / mL to about 450 mg / mL, about 150 mg / mL to about 400 mg / mL, about 150 mg / mL to about 350 mg / mL, about 150 mg / mL to about 300 mg / mL, about 150 mg / mL to about 250 mg / mL, or about 150 mg / mL to about 200 mg / mL.
168. The method of any one of claims 166 or 167, wherein the single unit dose comprises a total antibody concentration of about 100 mg / mL, about 101 mg / mL, about 102 mg / mL, about 103 mg / mL, about 104 mg / mL, about 105 mg / mL, about 106 mg / mL, about 107 mg / mL, about 108 mg / mL, about 109 mg / mL, about 110 mg / mL, about 111 mg / mL, about 112 mg / mL, about 113 mg / mL, about 114 mg / mL, about 115 mg / mL, about 116 mg / mL, about 117 mg / mL, about 118 mg / mL, about 119 mg / mL, about 120 mg / mL, about 121 mg / mL, about 122 mg / mL, about 123 mg / mL, about 124 mg / mL, about 125 mg / mL, about 126 mg / mL, about 127 mg / mL, about 128 mg / mL, about 129 mg / mL, about 130 mg / mL, about 131 mg / mL, about 132 mg / mL, about 133 mg / mL, about 134 mg / mL, about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about 140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, about 145 mg / mL, about 146 mg / mL, about 147 mg / mL, about 148 mg / mL, about 149 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, or about 500 mg / mL.
169. The method of any one of claims 166 to 168, wherein the single unit dose comprises a total antibody concentration of about 105 mg / mL, about 120 mg / mL, about 126 mg / mL, about 128 mg / mL, about 140 mg / mL, about 144 mg / mL, about 150 mg / mL, or about 160 mg / mL.
170. The method of any one of claims 166 to 169, wherein the single unit dose comprises a volume of about 0.001 mL to about 20 mL.
171. The method of any one of claims 166 to 170, wherein the single unit dose comprises a volume of about 0.001 mL, about 0.005 mL, about 0.010 mL, about 0.015 mL, about 0.020 mL, about 0.025 mL, about 0.030 mL, about 0.035 mL, about 0.040 mL, about 0.045 mL, about 0.050 mL, about 0.055 mL, about 0.060 mL, about 0.065 mL, about 0.070 mL, about 0.075 mL, about 0.080 mL, about 0.085 mL, about 0.090 mL, about 0.095 mL, about 0.100 mL, about 0.150 mL, about 0.200 mL, about 0.250 mL, about 0.300 mL, about 0.350 mL, about 0.400 mL, about 0.450 mL, about 0.500 mL, about 0.550 mL, about 0.600 mL, about 0.650 mL, about 0.700 mL, about 0.750 mL, about 0.800 mL, about 0.850 mL, about 0.900 mL, about 0.950 mL, about 1 mL, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL, about 1.5 mL, about 1.6 mL, about 1.7 mL, about 1.8 mL, about 1.9 mL, about 2 mL, about 2.1 mL, about 2.2 mL, about 2.3 mL, about 2.4 mL, about 2.5 mL, about 2.6 mL, about 2.7 mL, about 2.8 mL, about 2.9 mL, about 3 mL, about 3.1 mL, about 3.2 mL, about 3.3 mL, about 3.4 mL, about 3.5 mL, about 3.6 mL, about 3.7 mL, about 3.8 mL, about 3.9 mL, about 4 mL, about 4.1 mL, about 4.2 mL, about 4.3 mL, about 4.4 mL, about 4.5 mL, about 4.6 mL, about 4.7 mL, about 4.8 mL, about 4.9 mL, about 5 mL, about 5.1 mL, about 5.2 mL, about 5.3 mL, about 5.4 mL, about 5.5 mL, about 5.6 mL, about 5.7 mL, about 5.8 mL, about 5.9 mL, about 6 mL, about 6.1 mL, about 6.2 mL, about 6.3 mL, about 6.4 mL, about 6.5 mL, about 6.6 mL, about 6.7 mL, about 6.8 mL, about 6.9 mL, about 7 mL, about 7.1 mL, about 7.2 mL, about 7.3 mL, about 7.4 mL, about 7.5 mL, about 7.6 mL, about 7.7 mL, about 7.8 mL, about 7.9 mL, about 8 mL, about 8.1 mL, about 8.2 mL, about 8.3 mL, about 8.4 mL, about 8.5 mL, about 8.6 mL, about 8.7 mL, about 8.8 mL, about 8.9 mL, about 9 mL, about 9.1 mL, about 9.2 mL, about 9.3 mL, about 9.4 mL, about 9.5 mL, about 9.6 mL, about 9.7 mL, about 9.8 mL, about 9.9 mL, about 10 mL, about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.5 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, about 11.5 mL, about 11.6mL, about 11.7 mL, about 11.8 mL, about 11.9 mL, about 12 mL, about 12.1 mL, about 12.2 mL, about 12.3 mL, about 12.4 mL, about 12.5 mL, about 12.6 mL, about 12.7 mL, about 12.8 mL, about 12.9 mL, about 13 mL, about 13.1 mL, about 13.2 mL, about 13.3 mL, about 13.4 mL, about 13.5 mL, about 13.6 mL, about 13.7 mL, about 13.8 mL, about 13.9 mL, about 14 mL, about 14.1 mL, about 14.2 mL, about 14.3 mL, about 14.4 mL, about 14.5 mL, about 14.6 mL, about 14.7 mL, about 14.8 mL, about 14.9 mL, about 15 mL, about 15.1 mL, about 15.2 mL, about 15.3 mL, about 15.4 mL, about 15.5 mL, about 15.6 mL, about 15.7 mL, about 15.8 mL, about 15.9 mL, about 16 mL, about 16.1 mL, about 16.2 mL, about 16.3 mL, about 16.4 mL, about 16.5 mL, about 16.6 mL, about 16.7 mL, about 16.8 mL, about 16.9 mL, about 17 mL, about 17.1 mL, about 17.2 mL, about 17.3 mL, about 17.4 mL, about 17.5 mL, about 17.6 mL, about 17.7 mL, about 17.8 mL, about 17.9 mL, about 18 mL, about 18.1 mL, about 18.2 mL, about 18.3 mL, about 18.4 mL, about 18.5 mL, about 18.6 mL, about 18.7 mL, about 18.8 mL, about 18.9 mL, about 19 mL, about 19.1 mL, about 19.2 mL, about 19.3 mL, about 19.4 mL, about 19.5 mL, about 19.6 mL, about 19.7 mL, about 19.8 mL, about 19.9 mL, or about 20 mL.
172. The method of any one of claims 166 to 171, wherein the single unit dose comprises a volume of about 8.4 mL, about 9 mL, about 9.6 mL, about 10 mL, about 12 mL, about 12.8 mL, about 15 mL, or about 16 mL.
173. The method of any one of claims 1 to 172, wherein the anti -LAG-3 antibody comprises a full-length antibody.
174. The method of any one of claims 1 to 173, wherein the anti-PD-1 antibody comprises a full-length antibody.
175. The method of any one of claims 1 to 174, wherein the anti-LAG-3 antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody.
176. The method of any one of claims 1 to 175, wherein the anti-PD-1 antibody comprises a monoclonal, human, humanized, chimeric, or multispecific antibody.
177. The method of claim 175 or 176, wherein the multispecific antibody comprises a dualaffinity re-targeting antibody, a dual variable domain immunoglobulin, or a bispecific antibody.
178. The method of any one of claims 1 to 172, wherein the anti-LAG-3 antibody and / or the anti-PD-1 antibody comprises a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.
179. The method of any one of claims 1 to 178, wherein the anti-LAG-3 antibody comprises BMS-986016 (relatlimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, ieramilimab), aLAG3(0414), aLAG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P 13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBI-110, EMB-02, IBI-323, LBL-007, ABL501, or an antigen binding portion thereof.
180. The method of any one of claims 1 to 179, wherein the anti-LAG-3 antibody comprises relatlimab, or an antigen binding portion thereof.
181. The method of any one of claims 1 to 180, wherein the anti-LAG-3 antibody comprises:(a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO:4;(b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO: 10, respectively;(c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively;(d) heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:l and 2, respectively; or(e) heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:21 and 2, respectively.
182. The method of any one of claims 1 to 181, wherein the anti-PD-1 antibody comprises nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDL0680, TSR-042, cemiplimab, JS001,PF-06801591, BGB-A317, BI 754091, INCSHR1210, GLS-010, AM-001, STI-1110, AGEN2034, MGA012, BCD- 100, IBB 08, SSI-361, or an antigen binding portion thereof.
183. The method of any one of claims 1 to 182, wherein the anti-PD-1 antibody comprises nivolumab, or an antigen binding portion thereof.
184. The method of any one of claims 1 to 183, wherein the anti-PD-1 antibody comprises:(a) CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the amino acid sequence set forth in SEQ ID NO: 14;(b) a heavy chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and a light chain variable region CDR1, CDR2, and CDR3 comprising the sequence set forth in SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, respectively;(c) heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:13 and 14, respectively; or(d) heavy and light chains comprising the amino acid sequences as set forth in SEQ ID NOs:ll and 12, respectively.
185. The method of any one of claims 166 to 184, wherein the single unit dose comprises about 80 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody.
186. The method of claim 185, wherein the single unit dose comprises a volume of about 12 mL.
187. The method of claim 185, wherein the single unit dose comprises a volume of about 9 mL.
188. The method of any one of claims 166 to 184, wherein the single unit dose comprises about 75 mg / mL of the anti-PD-1 antibody and about 75 mg / mL of the anti-LAG-3 antibody.
189. The method of any one of claims 188, wherein the single unit dose comprises a volume of about 12.8 mL.
190. The method of any one of claims 188, wherein the single unit dose comprises a volume of about 9.6 mL.
191. The method of any one of claims 166 to 184, wherein the single unit dose comprises about 72 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody.
192. The method of any one of claims 191, wherein the single unit dose comprises a volume of about 10 mL.
193. The method of any one of claims 166 to 184, wherein the single unit dose comprises about 64 mg / mL of the anti-PD-1 antibody and about 64 mg / mL of the anti-LAG-3 antibody.
194. The method of claim 193, wherein the single unit dose comprises a volume of about 15 mL.
195. The method of any one of claims 166 to 184, wherein the single unit dose comprises about 60 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody.
196. The method of claim 195, wherein the single unit dose has a volume of about 16 mL.
197. The method of claim 195, wherein the single unit dose has a volume of about 12 mL.
198. The method of any one of claims 166 to 184, wherein the single unit dose comprises about 64.3 mg / mL of the anti-PD-1 antibody and about 85.7 mg / mL of the anti-LAG-3 antibody.
199. The method of claim 198, wherein the single unit dose has a volume of about 8.4 mL.
200. The method of any one of claims 166 to 184, wherein the single unit dose comprises about 60 mg / mL of the anti-PD-1 antibody and about 80 mg / mL of the anti-LAG-3 antibody.
201. The method of claim 200, wherein the single unit dose has a volume of about 9 mL.
202. The method of any one of claims 166 to 184, wherein the single unit dose comprises about 54 mg / mL of the anti-PD-1 antibody and about 72 mg / mL of the anti-LAG-3 antibody.
203. The method of claim 202, wherein the single unit dose has a volume of about 10 mL.
204. The method of any one of claims 166 to 184, wherein the single unit dose comprises about 45 mg / mL of the anti-PD-1 antibody and about 60 mg / mL of the anti-LAG-3 antibody.
205. The method of claim 204, wherein the single unit dose has a volume of about 12 mL.
206. The method of any one of claims 1 to 205, wherein the anti-LAG-3 antibody comprises relatlimab, or an antigen binding portion thereof, and the anti-PD-1 antibody comprises nivolumab, or an antigen binding portion thereof.
207. The method of any one of claims 1 to 206, wherein the endoglycosidase hydrolase enzyme cleaves hyaluronic acid at a hexosaminidic P (1-4) or (1-3) linkage.
208. The method of any one of claims 1 to 207, wherein the endoglycosidase hydrolase enzyme comprises a catalytic domain of hyaluronidase PH-20 (HuPH20), HYAL1, HYAL2, HYAL3, HYAL4, orHYALPSl.
209. The method of any one of claims 1 to 207, wherein the endoglycosidase hydrolase enzyme comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to amino acids 36-490 of SEQ ID NO:87.
210. The method of any one of claims 1 to 209, wherein the endoglycosidase hydrolase enzyme comprises a hyaluronidase.
211. The method of claim 210, wherein the hyaluronidase comprises HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, or a variant or isoform thereof.
212. The method of any one of claims 1 to 211, wherein the endoglycosidase hydrolase enzyme comprises rHuPH20 or a fragment thereof.
213. The method of any one of claims 1 to 212, wherein the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising one or more amino acid substitutions relative to a wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof.
214. The method of any one of claims 1 to 213, wherein the endoglycosidase hydrolase enzyme comprises a modified hyaluronidase comprising (i) one or more amino acid substitution in an alpha-helix region, (ii) one or more amino acid substitution in a linker region, (iii) deletion of one or more N-terminal and / or C-terminal amino acids, or (iv) any combination of (i)-(iii), relative toa wild-type hyaluronidase that is HuPH20, HYAL1, HYAL2, HYAL3, HYAL4, HYALPS1, or a fragment thereof.
215. The method of any one of claims 1 to 214, wherein the endoglycosidase hydrolase enzyme comprises a modified rHuPH20, wherein the modified rHuPH20 comprises:(a) one or more amino acid substitution in an alpha-helix region, a linker region, or both an alpha-helix region and a linker region relative to wild-type rHuPH20;(b) deletion of one or more N-terminal amino acid, one or more C-terminal amino acid, or one or more N-terminal amino acid and one or more C-terminal amino acid relative to wild-type rHuPH20; or(c) both (a) and (b).
216. The method of any one of claims 1 to 215, wherein the tumor comprises a hepatocellular carcinoma, colorectal cancer, gastric cancer, small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), squamous NSCLC, nonsquamous NSCLC, solid cancer with liver metastatic disease, cervical cancer, breast cancer, triple-negative breast cancer, pancreatic cancer, urothelial cancer, prostate cancer, hormone refractory prostate adenocarcinoma, hematological cancer, squamous cell carcinoma, glioma, gastrointestinal cancer, renal cancer, clear cell carcinoma, ovarian cancer, liver cancer, endometrial cancer, kidney cancer, renal cell carcinoma (RCC), thyroid cancer, neuroblastoma, glioblastoma, glioblastoma multiforme, stomach cancer, bladder cancer, hepatoma, colon cancer, head and neck cancer, gastroesophageal cancer, germ cell tumor, pediatric sarcoma, sinonasal natural killer T-cell lymphoma, melanoma, bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, rectal cancer, solid tumor of childhood, cancer of the ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumor, brain cancer, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, environmentally-induced cancer, virus-related cancer or cancer of viral origin, or a combination thereof.
217. The method of any one of claims 1 to 216, wherein the tumor is recurrent or refractory.
218. The method of any one of claims 1 to 217, wherein the tumor is unresectable, advanced, and / or metastatic.
219. The method of any one of claims 1 to 218, wherein the tumor is a malignant tumor.
220. The method of any one of claims 1 to 219, wherein the dose of the anti -LAG-3 antibody, anti-PD-1 antibody, and / or endoglycosidase hydrolase enzyme is a flat dose.
221. The method of any one of claims 1 to 6, 10 to 13, 17 to 20, 24 to 36, 39 to 43, 46 to 50, 53 to 57, 60 to 64, 69 to 71, 76 to 78, 83 to 85, 90 to 92, 97, 126 to 131, 138 to 143, 149 to 157, 161 to 163, 166 to 197, or 206 to 220, wherein the minimum serum concentration at day 28 (CminD28), the average serum concentration at day 28 (CavgD28), the minimum serum concentration at steady state (CminSS), and / or the average serum concentration at steady state (CavgSS) of the anti-PD-1 antibody in the subject is about equal to or greater than the geometric mean CminD28, CavgD28, CminSS, and / or CavgSS, respectively, of nivolumab in a population of subjects in which 480 mg of nivolumab is intravenously administered once about every four weeks to each subject in the population.
222. The method of any one of claims 1 to 36, 42, 43, 48 to 50, 55 to 57, 62, 70, 71, 76 to 78, 83, 91, 92, 97, 126 to 131, 138 to 143, 149 to 157, 163, or 166 to 220, wherein the CminD28, CavgD28, CminSS, and / or CavgSS of the anti-LAG-3 antibody in the subject is about equal to or greater than the geometric mean CminD28, CavgD28, CminSS, and / or CavgSS, respectively, of relatlimab in a population of subjects in which 480 mg of relatlimab is intravenously administered once about every four weeks to each subject in the population.
223. The method of any one of claims 1 to 34, 39 to 41, 46 to 48, 53 to 55, 60 to 64, 69, 84, 85, 90, 98, 99, 104 to 106, 111 to 113, 118 to 120, 125 to 131, 138 to 143, 149 to 157, 161, 162, 164, or 166 to 220, wherein the CminD28, CavgD28, CminSS, and / or CavgSS of the anti-LAG-3 antibody in the subject is about equal to or greater than the geometric mean CminD28, CavgD28, CminSS, and / or CavgSS, respectively, of relatlimab in a population of subjects in which 360 mg of relatlimab is intravenously administered once about every three weeks to each subject in the population.
224. The method of any one of claims 1 to 223, wherein the method further comprises administering an additional anti-cancer therapy.
225. The method of claim 224, wherein the additional anti-cancer therapy comprises a surgery, a radiation therapy, a chemotherapy, an immunotherapy, or any combination thereof.
226. The method of claim 224 or 225, wherein the additional anti-cancer therapy comprises a chemotherapy.
